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Abstract 
 
Neuroinflammation is an early feature of a number of nervous system disorders. 
Inflammation in the brain is primarily mediated via microglial cells, which are active 
components of circuit development in the central nervous system. Schizophrenia is 
a psychiatric illness with deficits in perceptual, cognitive and emotional function. 
Prior to the onset of psychosis, there is a period of attenuated psychotic symptoms, 
where individuals experience sub threshold features of psychosis. This ‘ultra high 
risk’ period can provide unique opportunities to investigate the development of 
psychosis. It has been demonstrated through translocator protein (TSPO) positron 
emission tomographic (PET) imaging that microglial activity is elevated in chronic 
schizophrenia, however it is unknown whether this elevation is present prior to the 
onset of psychosis. It is also uncertain what effect antipsychotic medication has on 
microglia in vivo. This thesis is divided between clinical and animal investigation, 
the results can be split into four findings; Firstly we demonstrate that there is a 
higher binding of [11C]PBR28 (a novel TSPO PET ligand) in ultra high risk subjects 
and patients with schizophrenia compared to healthy controls. Symptoms in the ultra 
high risk subjects also correlate with the level of ligand binding. Secondly, brain 
volumes are not correlated with [11C]PBR28 binding or inflammatory cytokine levels 
in peripheral blood samples. The third finding of this thesis is that antipsychotic drug 
administration does not appear to alter cortical microglial cells in naïve and 
systemically inflamed animals. The final finding is that brain volume is reduced by 
antipsychotic medication. Together these findings demonstrate that inflammation is 
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present in subjects experiencing subthreshold psychotic symptoms. The animal 
experiments suggest medicated patients would not be expected to have higher 
levels of microglial activity than their un-medicated counterparts. Further 
investigation is needed to determine the mechanism of cortical volume changes 
after medication and how this relates to TSPO. 
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Psychosis and Schizophrenia 
Schizophrenia  
The term schizophrenia was first proposed by Eugen Bleuler in 1911 to describe a 
mental illness with an apparent split of conscious thought segregation from reality 
(‘schizo’ split, ‘phrene’ mind). It is a chronic disorder of perceptual, cognitive and 
emotional function. The combination of symptoms is distressing and disabling and 
has a huge impact on the individual, as well as those providing support. The 
healthcare burden of schizophrenia is prominent in both developed and developing 
countries (Howes and Murray, 2014). For the purposes of research, the symptoms 
of schizophrenia are commonly assessed on the positive and negative syndrome 
scale (PANSS), which is a summation of the positive (hallucinations and delusions), 
negative (depressive and social functioning) and general symptoms which comprise 
the disease state. The aetiology and underlying mechanisms of schizophrenia have 
not yet been fully elucidated; however dopamine and glutamate are thought to be 
two main transmitter system abnormalities which contribute to the disease.  
Clinical features and diagnosis of schizophrenia  
The diagnosis of schizophrenia is made through clinical interview using a diagnostic 
schedule such as the diagnostic and statistical manual of mental disorders (DSM 
IV, a later edition, DSM-5 has been published, however this was not available at the 
start of the studies presented here (American Psychiatric et al., 2013; Bell, 2001)). 
The diagnostic criteria for schizophrenia, specified by the American Psychiatric 
Association in DSM IV are as follows; 
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“Characteristic symptoms:  
A. Two (or more) of the following, each present for a significant portion of time during 
a 1-month period (or less if successfully treated):  
(1) delusions  
(2) hallucinations  
(3) disorganized speech (e.g., frequent derailment or incoherence  
(4) grossly disorganized or catatonic behaviour  
(5) negative symptoms, i.e., affective flattening, alogia (poverty of speech), or 
avolition (lack of motivation) Note: Only one Criterion A symptom is required if 
delusions are bizarre or hallucinations consist of a voice keeping up a running 
commentary on the person's behavior or thoughts, or two or more voices conversing 
with each other.  
B. Social/occupational dysfunction: For a significant portion of the time since the 
onset of the disturbance, one or more major areas of functioning such as work, 
interpersonal relations, or self-care are markedly below the level achieved prior to 
the onset (or when the onset is in childhood or adolescence, failure to achieve 
expected level of interpersonal, academic, or occupational achievement).  
C. Duration: Continuous signs of the disturbance persist for at least 6 months. This 
6-month period must include at least 1 month of symptoms (or less if successfully 
treated) that meet Criterion A (i.e., active-phase symptoms) and may include periods 
of prodromal (symptomatic of the onset) or residual symptoms. During these 
prodromal or residual periods, the signs of the disturbance may be manifested by 
only negative symptoms or two or more symptoms listed in Criterion A present in an 
attenuated form (e.g., odd beliefs, unusual perceptual experiences).  
Neuroinflammation and psychosis; antipsychotic medication. Peter Bloomfield 
 
25 
 
D. Schizoaffective and Mood Disorder exclusion: Schizoaffective Disorder and 
Mood Disorder With Psychotic Features have been ruled out because either (1) no 
Major Depressive Episode, Manic Episode, or Mixed Episode have occurred 
concurrently with the active-phase symptoms; or (2) if mood episodes have occurred 
during active-phase symptoms, their total duration has been brief relative to the 
duration of the active and residual periods.  
E. Substance/general medical condition exclusion: The disturbance is not due to the 
direct physiological effects of a substance (e.g., a drug of abuse, a medication) or a 
general medical condition.  
F. Relationship to a Pervasive Developmental Disorder: If there is a history of 
Autistic Disorder or another Pervasive Developmental Disorder, the additional 
diagnosis of Schizophrenia is made only if prominent delusions or hallucinations are 
also present for at least a month (or less if successfully treated). 
Epidemiology  
Schizophrenia is estimated to affect more than 21 million people worldwide, with 
many of these being in developing countries. Half of those with schizophrenia do 
not receive care for their condition. Those with schizophrenia are 2-2.5 times more 
likely to die early, often as a result of comorbid illnesses including cardiovascular, 
metabolic and infectious diseases. For example, the prevalence of diabetes is up to 
3 times higher in populations of patients with schizophrenia (WHO statement on 
schizophrenia and public health  
http://www.who.int/mental_health/media/en/55.pdf?ua=1 Accessed 19/03/2015). 
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Age and sex effects  
Sex effects have widely been reported in schizophrenia, both historically from a 
demographic perspective (Kraepelin, 1893) and in modern investigations using 
clinical imaging modalities relating to cortical structural differences (Nasrallah et al., 
1990). Schizophrenia is more prevalent in men than women (~4:3 ratio men to 
women (McGrath et al., 2008)), however the reason for this is unknown. A milder 
progression and better prognosis following diagnosis is observed in female patients 
(Ochoa, 2012). Indeed a greater proportion of female patients respond to treatment 
and there is also generally a later onset in women than in men (18-25 in men, 25-
35 in women (Ochoa, 2012)). A number of sexual dimorphisms in developmental 
and mature neurobiology are evident including protein, transmitter and structural 
differences (Martins-de-Souza et al., 2010). However a sufficient explanation in 
these differences is currently unknown. Clinical studies generally recruit male and 
female participants for investigation, however animal literature is largely biased on 
investigations in male animals (Clayton, 2014), which limits the applicable 
physiological observations to be applied as clinical theory. Recent policy changes 
have been considered with the aim of establishing a sex balance for animal studies 
(Clayton, 2014). 
Ultra High Risk (UHR) for psychosis 
Clinical features subthreshold to diagnosis can be a precursor to the development 
of a specific disorder. This is true of somatic and mental health disorders. Individuals 
with subthreshold depressive symptoms are at a higher risk of developing major 
depression than the general population (Cuijpers and Smit, 2004). Indeed the same 
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effect is apparent with psychosis and psychotic like symptoms. Preventative 
measures and intervention at this early stage may help prevent the occurrence of a 
fully developed psychotic disorder. Individuals experiencing these subthreshold 
symptoms can be identified and provide a unique opportunity for the investigation 
of psychotic disorder. Not all individuals at ultra high risk (UHR) will transition to 
psychosis, the literature is variable, with transition rates reported between 15-30% 
(Cannon et al., 2015; Howes, 2011; Perkins et al., 2014; Wood et al., 2008; Yung et 
al., 2005), hence longitudinal follow up can provide useful insights into the 
differences between transitioning individuals and those who stay subthreshold. 
Onset of features associated with psychosis risk can develop from as early as 15, 
with psychological symptoms becoming apparent shortly after, the progression of 
psychosis and the start of treatment is outlined in Figure 1. (adapted from 
(McGlashan and Hoffman, 2000)). Criteria for risk can be assessed on the 
‘comprehensive assessment of the at risk mental state’ (CAARMS). This clinical 
scale is similar to the PANSS used for schizophrenia, but assesses the more subtle 
features of pre-clinical psychotic like and other symptoms seen in the prodrome to 
psychosis (Yung et al., 2005). The outcome of UHR subjects is difficult to predict, 
while a modest number of individuals make the transition to first episode psychosis, 
many return to sub threshold clinical symptoms, and others will be diagnosed with 
related psychiatric disorders (Yung et al., 2005). 
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Figure 1. Onset and progression of psychosis  
Prodromal and high risk subjects are those with psychological symptoms prior to first episode treatment. Adapted from 
(McGlashan and Hoffman, 2000).
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Grey and white matter alterations in psychosis 
In people with psychosis cortical morphology is altered (Cannon et al., 2014). 
Functional decline and cortical abnormalities correspond developmentally, through 
prodromal periods, into the first psychotic episode and plateau for a state of maximal 
chronicity (McGlashan and Hoffman, 2000). Gene pathway analysis of 
schizophrenia has implicated synaptic and postsynaptic genes (Consortium, 2015). 
In addition to alterations in connectivity and genetic disruption in synapse 
associated pathways in established psychosis, gross cortical morphology is also 
altered in the early stages, when psychotic like symptoms first present (Cannon et 
al., 2014). Longitudinal imaging of cortical thickness has demonstrated a higher rate 
of decline in subjects who transition from clinical high risk to first episode psychosis 
(Cannon et al., 2015). Furthermore, decline in cortical thickness is accompanied by 
elevated levels of inflammatory plasma markers (Cannon et al., 2014; Perkins et al., 
2014). Grey and white matter are both disrupted in psychosis and schizophrenia, 
however grey matter appears to have a more severe course of decline (Wood et al., 
2008). The directionality of change differs between grey and white matter, with grey 
matter reducing in volume (Pantelis et al., 2003a) and white matter increasing in 
volume in the prodrome (Walterfang et al., 2008). 
Transmitter abnormalities  
Similar to the modifications seen in cortical morphology, there appears to be an 
alteration in prodromal cortical transmitter function. Dopaminergic transmitter 
dynamics are markedly altered in schizophrenia (Abi-Dargham et al., 2002; Seeman 
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and Kapur, 2000), which broadly relate, but are not confined, to striatal 
hyperdopaminergia and prefrontal cortical hypodopaminergia (Howes and Kapur, 
2009) and elevated striatal dopamine synthesis capacity (Bose et al., 2008; Howes, 
2011), which are predictive of the transition of high risk subjects to first episode 
psychosis (Howes, 2011). Alongside dopamine, hypofunctional glutamate signalling, 
particularly through the NMDA receptors, is apparent in schizophrenia (Howes et 
al., 2015). The dopamine and glutamate hypotheses likely both hold explanations 
for the pathophysiology of schizophrenia, however PET evidence of glutamate 
disruption has not been possible to acquire, as reliable techniques are not currently 
available. MRS (magnetic resonance spectroscopy) has however been able to 
demonstrate a difference in glutamate in the prefrontal cortex of patients with 
schizophrenia and the prodrome (Fusar-Poli et al., 2011; Marsman et al., 2013; 
Stone et al., 2010). 
Antipsychotic drugs 
Antipsychotic medications are prescribed to individuals experiencing psychotic 
symptoms and are the primary treatment for patients with schizophrenia. As well as 
being used to treat schizophrenia, many individuals with early stage symptoms of 
psychosis are prescribed low doses of these drugs to ameliorate symptoms 
(Miyamoto et al., 2004). Antipsychotic drugs are also prescribed to those with 
depression (Pisa et al., 2014), and used in the treatment of traumatic brain injury 
(Elovic, 2008) and dementia (Park et al., 2015b). While the positive symptoms 
associated with psychosis are improved by drug treatment, the full consequences 
of antipsychotic drug treatment are not entirely understood. Antipsychotic drugs can 
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be divided into a number of subtypes, based around when they were first 
synthesized or their constitutive receptor occupancy. First generation (or typical) 
antipsychotics (FGAs) such as haloperidol were the earliest antipsychotics to be 
prescribed. The primary mode of action for a FGA is at the D2 dopamine receptor, 
where the drug acts as a competitive antagonist. The dopamine hypothesis of 
schizophrenia, where hyperdopaminergia acts as the cause of the positive 
symptoms of schizophrenia, arose from the discovery of FGA action on D2 receptors 
(Seeman and Kapur, 2000). Second generation antipsychotics (SGAs) also have a 
dopaminergic action, however SGAs are far less specific in their action, often with 
serotonergic augmentation (Miyamoto et al., 2004). The broader spectrum of 
antagonism has been useful in addressing the positive and negative symptoms 
together (Miyamoto et al., 2012). The cortical consequences of antipsychostic drugs 
have been investigated in vivo and in vitro, however the results have often conflicted 
or have not been investigated independently of a disease model. Non-human 
primate investigation of haloperidol and olanzapine demonstrated an 8-11% 
reduction in the cortex of all treated animals (Dorph-Petersen et al., 2005). More 
recently investigations using microMRI in rats dosed with antipsychotics has 
demonstrated how, over a number of weeks, animals receiving haloperidol exhibit 
distinct reductions in cortical volume (Vernon et al., 2011). Later in this chapter we 
will see more literature relating to the action of antipsychotic medication in more 
detail. When assessing cortical changes associated with psychosis and 
schizophrenia, it is difficult to separate antipsychotic associated changes and those 
changes arising from the progression of the disease. Hence high risk for psychosis 
subjects can provide insights to the separation of disease and medication.  
Neuroinflammation and psychosis; antipsychotic medication. Peter Bloomfield 
 
32 
 
Microglia and Neuroinflammation  
There are 3 main classes of glia in the CNS (oligodendrocytes, astrocytes and 
microglia) which perform distinct functions. Oligodendrocytes provide myelination of 
neurons in the CNS, astrocytes are involved in transmitter metabolism and ion 
homeostasis, as well as being reactive to inflammatory stimuli (Zhang, 2001). 
Microglia have a myeloid origin and act as the residing immune cells of the brain 
and spinal cord, however recent evidence has demonstrated wider roles for the 
cells. 
Neuroinflammation is broadly characterised as a response within the central 
nervous system mediated by either resident or infiltrating inflammatory cells. The 
subtleties of these glia have been debated for over a century and have an incredibly 
diverse morphological and physiological range. After Ramon y Cajal’s initial 
observations of the cells in 1913 (Cajal, (1913) ), del Rio-Hortega further 
investigated the cellular microglial phenotype as well as suggesting a potential 
phagocytic function in the CNS (del Río-Hortega, 1918). 
Microglial origin and developmental involvement 
The blood brain barrier (BBB) segregates the brain parenchyma from the blood 
borne immune protection of white blood cells, hence this intrinsic population of cells 
is required for health and immune protection. These unique cells are derived from a 
haematopoietic cell lineage and share the same progenitor as granulo/mono-cytic 
cells (including dendritic cells Figure 2 (Ransohoff and Cardona, 2010)).
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Figure 2. Myeloid origins of microglial cells  
Unlike other CNS cells, microglia originate from a myeloid cell lineage rather than neuroectodermal. Adapted from (Ransohoff 
and Cardona, 2010).
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While microglia are components of the CNS, they are mononuclear cells that share 
many common traits with blood borne immune cells. Although initially segregated 
from the ectoderm located neuronal and macroglial origin, microglia can be 
observed migrating, or in close proximity, to ectodermal tissue between E7 and E9 
(Ginhoux et al., 2010). Microglia are active pruners of synapses in the postnatal 
brain, engulfing synaptic elements with their processes, providing a more concise 
synaptic network. Indeed, mice with deficient microglial signalling (through a 
CX3CR1 KO (knockout)) have reduced amounts of developmental synaptic pruning 
(Paolicelli et al., 2011).  
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Types of response 
In healthy brain tissue, microglia are present in a ‘quiescent’ state, where the cell 
morphology consists of a relatively small soma and ramified processes extending 
out into the local environment (Figure 3). 
 
Figure 3. Ramified microglia  
Ramified microglia (green, nuclei in red) in healthy rat brain tissue, with ramified 
processes (white arrows) and minimal soma area (Purple arrows). Image from 
control rat brain tissue stained with Iba-1 for microglia and DAPI nuclei. Scale bar = 
20 µm. 
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The microglial soma will generally be present in a hull of a 5-10 µm radius, whereas 
the processes can extend into the local environment depending on the state of 
activity (Lawson, 1990;). As will be discussed, the functions carried out in this 
morphological context are comparatively diverse. Microglial cell morphology 
changes rapidly depending on environmental signals, which can be chemical or 
physical in nature. Many examples in the literature refer to M1 and M2 response 
phenotypes of microglia. This terminology has arisen from myeloid cell lineage 
response patterns, where the characteristics of microglia have been thought of in 
terms of their association with inflammation and types of inflammatory response. In 
a broad sense, the M1 response is pro-inflammatory and associated with tissue 
destructive activity. The M2 response is thought to be an anti-inflammatory response 
with neuro-protective features serving to reduce inflammation (Turtzo et al., 2014). 
Microglial signalling 
Microglia are a highly motile cell type, which respond to and release chemokines 
and cytokines. Peripheral levels of cytokines are often observed alongside central 
evidence of microglial activity (Kettenmann et al., 2011). Whether the peripheral 
cytokines are as a result of central release, or vice-versa, is unknown. However, it 
is unlikely that such levels would be produced purely as a result of the central 
cellular activity, rather a state of systemic inflammation would potentially link central 
and peripheral processes (Dieset et al., 2015; Reuben et al., 2002). Microglia have 
a vast range of receptors expressed on their membrane (Table 1) and can respond 
to neurotransmitters (Domercq et al., 2013; Mead et al., 2012; Pocock and 
Kettenmann, 2007) as well as other, more primarily inflammatory signals. The 
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response of microglial cells to these signals have been investigated in vitro and in 
vivo to demonstrate how diverse their responses can be. It has long been 
established that microglial cells stimulated in vitro undergo a distinct membrane 
depolarization (Kettenmann et al., 1993). The utility of this depolarization remains 
unknown. More recent experiments have revealed an NMDA receptor association 
with the membrane potential as it is altered with the administration of MK801, an 
NMDA receptor antagonist (Morkuniene et al., 2015). 
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Receptor Subtypes Functional activity including; 
Glutamate 
/AMPA 
mRNA flop 
variants of GluR2 
and GluR4 
Glutamate 
(metabotropic) 
mRNA flip variants 
of GluRs 1–4, 
Modulate TNF-α 
release. 
NR1 subunit 
expressed after 
transient forebrain 
ischaemia 
mGluR1 and 
mGluR5a mRNA 
GluR1 and GluR3 in flip form. 
No functional activity shown so far. 
Agonist 1S,3R-ACPD induces increased 
Ca2+. 
GABA GABA(B), 
GABA(B1a), 
GABA(B1b) and 
GABA(B2) proteins 
Stimulation of GABAB leads to activation 
of a K+ conductance; attenuates LPS-
induced interleukin release. 
ATP & purinergic Gi/Go-coupled P2Y 
(Y1, Y2 Y4 and 
Y12), P2X (X1, X4 
and X7) P2Y8 and 
P2X6 mRNA and 
protein 
Modulate movement of microglial fine 
processes. 
Activation induces chemotaxis. mRNA 
and receptor protein is upregulated on 
microglia after neuronal injury; functions 
as a mediator of microglial phagocytosis; 
responds to UDP. 
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Triggers TNF-α release. Modulates 
superoxide production. Activation 
implicated in neuropathic pain pathways. 
Activation induces chemotaxis. 
Adenosine A2aA3 Induces expression of NGF, COX-2 
mRNA and synthesis of PGE2. 
Suppresses LPS-induced TNF-α 
release. 
Cholinergic α7 nAChR subunit ACh or nicotine inhibits LPS-induced 
TNF-α release. 
Nicotine attenuates gp120 or IFNγ-
induced microglia activation. 
Cannabinoid CB2 receptor 
expressed in 
perivascular 
microglia 
CB1 CB2 and abn-
CBD 
Activation reduces microglial toxicity and 
cytokine secretion. 
Present on cultured microglia. 
Non-specific activation of cannabinoid 
receptors suppresses microglial 
activation and neurotoxicity. 
Adrenergic mRNA for α1 α2 β1 
and β2 (but not β3) 
Agonists decrease mRNA for IL-6 and 
TNF-α. Functional noradrenergic 
receptors identified on cultured microglia 
and in acutely isolated brain slices; 
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modulates membrane currents; 
suppresses cytokine and NO release. 
Dopamine D1- and D2-like 
receptors, 
expression inferred 
from function 
Functional dopamine receptors identified 
on cultured microglia and in acutely 
isolated brain slices; modulates 
membrane currents; suppresses NO 
release; promotes migration. 
Opioid   MOR and KOR 
mRNA 
Evidence of MOR and KOR function and 
an opioid-receptor-independent pathway. 
Agonists induce ameboid phenotype in 
microglia, chemotaxis and BDNF-gene 
expression. 
Morphine inhibits C5a and RANTES 
chemotaxis and LPS- or IL-1β-induced 
production of RANTES. 
Neuropeptides neurokinin-1 (NK-1) 
B1 and B2 
VPAC1 
Modulates chemotaxis; activates of 
NADPH oxidase. 
Increases microglial motility; releases 
NO and PGE2. 
Inhibits production of inflammatory 
chemokines and cytokines. 
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Table 1. Receptors on microglia  
Adapted from (Pocock and Kettenmann, 2007). 
  
Neuroinflammation and psychosis; antipsychotic medication. Peter Bloomfield 
 
42 
 
Physiology and morphology  
Neuroinflammation is commonly initiated by an insult to the CNS and can be as a 
result of physical (traumatic injury) or chemical (pathogenic substance) insults. 
Microglia, for a long time, were considered to be ‘sentinels’, with an observational 
role as the extent of their habitual function. However it is increasingly evident that a 
much more elaborate function exists (Tremblay et al., 2011). In the quiescent state 
microglial cells display a ramified morphology, with numerous processes extending 
through the local environment.  
Figure 4 demonstrates the two traditionally accepted morphological states of 
microglial cells, ramified and amoeboid (left and right respectively). The cytokines 
associated with the two broad microglial morphologies in Figure 4 are markers of 
inflammation, or inflammatory response, particularly associated with 
neurodegenerative processes. Interleukin 1β (IL-1β) (Lim and Marsland, 2013) and 
interleukin 6 (IL-6) in the periphery are considered hallmark features of inflammation 
and are predictive of age related cognitive decline and mortality in psychosis 
(Reuben et al., 2002). Functional roles of microglia are often associated with tissue 
repair and phagocytosis of potentially harmful material (Weitz and Town, 2012). 
These examples demonstrate the complex nature of microglial biology from the CNS 
and peripheral domains. 
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Figure 4. Microglial morphology  
Microglial cells are thought to largely exist in two morphological states, ramified (A) 
with processes extending into the surrounding environment, or amoeboid, with a 
swollen cell body with retracted processes (B) (Weitz and Town, 2012). 
 
It is increasingly clear that the binary model in Figure 4 is a simplified representation 
and that these are two distinct points on a spectrum of morphology and function. It 
is unclear how much overlap in function exists on the spectrum between these two 
points. There are environments where microglia will have cues to be responsive to 
A B 
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inflammation, synaptically involved and phagocytic. It is not currently known how 
the cellular morphology would be affected in each state. While microglial cells are 
the primary mediators of a neuroinflammatory response (Chen et al., 2012), they 
require an initial signal to respond to. In many cases, this signal takes the form of 
cytokine signalling after an injury. For example tissue damage stimulates the 
release of cytokines, which in turn attract microglia to the site of injury and cause 
an activity response (Stence et al., 2001). During plasticity and development, the 
regulation of microglial activity is not currently known, however plasticity associated 
microglial activity can be altered experimentally (Parkhurst et al., 2013). While there 
is a considerable body of literature demonstrating the roles of healthy and diseased 
function separately, the reality is more likely to be a combination of functions in 
varying proportions in a context dependent manner. 
Synaptic roles  
Traditional function of ramified processes was thought to be for monitoring of 
extracellular alterations. However, evidence is now accumulating for the 
involvement of microglia in synaptic dynamics (Nimmerjahn et al., 2005; Paolicelli 
et al., 2011; Parkhurst et al., 2013; Tremblay et al., 2010). Recent evidence also 
suggests whole synapses, and neurons, can be phagocytosed by microglial cells 
(Kettenmann et al., 2013), the trigger for such an extreme response is currently 
unknown. Microglia are further involved in synaptic processes in the adult brain. 
Tremblay et al., (2010) demonstrate how altering visual experiences, known to 
induce plasticity, were able to change the interaction between microglia and 
synapses. A potential signalling mechanism for plasticity responses is brain derived 
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neurotrophic factor (BDNF), blocking BDNF signalling can inhibit learning 
dependent synapse formation (Parkhurst et al., 2013). Microglial cells are restricted 
to the CNS, being present in both the brain and spinal cord. The density of cells 
varies across regions, as the local function dictates the morphology of cells as well 
as the density of the population. Long-range signalling is able to cause a change in 
microglial cell density depending on their requirement centrally (Mittelbronn, 2001; 
Savchenko et al., 1997). The distribution of microglia alters over time and with 
demographic variation in populations. The number of microglia in the cortex are 
increased with age (Norden and Godbout, 2013) as well as with obesity (Thaler et 
al., 2013). Similarly, peripheral cytokine levels are elevated in these situations (Lim 
and Marsland, 2013; Vgontzas et al., 1997), suggesting a potential crosstalk 
between CNS and the periphery. 
Microglia in schizophrenia 
A number of PET and post mortem tissue studies have established that microglia l 
activity is elevated in patients with schizophrenia (see Table 2 & Table 3 
respectively). The PET literature varies from regions with higher hippocampal 
microglial activity (van Berckel et al., 2008), to subtle grey matter elevations 
(Doorduin et al., 2009) or a symptom correlation (Takano et al., 2010). There is a 
range of reports of microglial changes in post mortem tissue, with hypertrophic 
morphology being a key observation (Bayer et al., 1999) although a large amount 
of controversy is apparent in the studies, with suggestions of an association with 
suicide (Schnieder et al., 2014; Steiner et al., 2008). It is apparent that microglia 
play a role in psychosis, or an aspect of psychopathology. A number of animal 
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models of schizophrenia are based on an immune insult early in the prenatal phase 
of life, in keeping with neurodevelopmental hypotheses of schizophrenia (Juckel et 
al., 2011; Zhu et al., 2014). 
All of the clinical studies to date have investigated patients with schizophrenia or 
recent onset psychosis in vivo, or end stage schizophrenia in post mortem tissue. 
Hence it is unclear at which stage of psychosis microglial activity elevation is 
evident. The stage of psychosis that microglial activity changes are occurring is one 
aspect of disorder we seek to address in this thesis.
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Reference  
(Sample size, case/control) 
Age in years 
(case/Ctl) 
Medication 
status 
Method of 
assessment 
Disorder status Methods Findings  (+, ~, -) 
(van Berckel et al., 2008) 
10/10 
24/23 Medicated DSM IV Recent onset 
schizophrenia (PANSS) 
In vivo PET 
[11C] -(R)- PK11195 
+ Grey matter ^ (p<0.05) 
(Doorduin et al., 2009) 
7/8 
31/27 Medicated DSM IV  Schizophrenia 
spectrum (PANSS) 
In vivo PET 
[11C] -(R)- PK11195 
+ Hippocampal ^ (p=0.004) 
30% increase in grey matter 
(Takano et al., 2010) 
14/14 
44/43 Medicated DSM IV Schizophrenia (PANSS) In vivo PET 
[11C] DAA1106 
~ Positive symptoms 
correlation p<0.0045 
(bonferroni 0.05/11) 
(Kenk et al., 2015) 
16/27 
43/44 Medicated DSM IV Schizophrenia with 
ongoing symptoms 
(PANSS) 
In vivo PET 
[18F] FEPPA 
~ NS difference 
 
Table 2. PET imaging studies of TSPO/microglia in schizophrenia 
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Reference  
(Sample size, case/ctl) 
Age in years 
(case/Ctl) 
Medication 
status 
Disorder status Methods Findings  (+, ~, -) 
(Bayer et al., 1999) 
(14/13) 
64/58 Medicated Schizophrenia, retrospective 
assessment with DSM-III 
HLA-DR staining + PFC & hippocampal microglial 
elevations, particularly in later 
onset (no stats) 
(Radewicz, 2000) 
(8/10) 
84/70 Medicated Schizophrenia DSM-III-R HLA-DR + dlPFC, ACC (p< 0.05) and 
temporal gyrus (p< 0.01) 
(Steiner et al., 2006) 
(16/16) 
55/58 Medicated Schizophrenia DSM-IV-R HLA-DR staining - in ACC and dlPFC, but + in 
hippocampus. 
(Steiner et al., 2008) 
(16/10) 
54/55 Medicated Schizophrenia DSM-IV HLA-DR staining + in dlPFC, ACC and thalamus 
(p< 0.05) 
(Kreisl et al., 2013) 
(45/47) 
55/42 Medicated Schizophrenia DSM-IV [3H]PBR28 
autoradiography 
+ ligand binding in dlPFC (p< 
0.011) 
(Schnieder et al., 2014) 
(25 Suicide/11NonSuicide) 
55/56 Medicated Schizophrenia with and without 
suicide 
Iba-1, CD68 
staining 
+ microglia in ventral PFC with 
suicide (0.033) 
 
Table 3. Post mortem tissue analysis of microglia in schizophrenia
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Antipsychotic medication and microglia 
All clinical investigations of microglia in psychosis to date have been confounded by 
antipsychotic medication. The experimental evidence for antipsychotic-microglial 
interaction is presented in Table 4. There are 16 investigations across cell culture 
and animal models demonstrating a range of responses by microglia to a number 
of antipsychotic medications, both first and second generation. The majority of 
studies demonstrate an anti-inflammatory action of antipsychotics on microglial 
cells. In a number of studies antipsychotic medications did not alter microglia either 
in morphology or physiological response. In vitro investigations have demonstrated 
an anti-inflammatory influence of a number of SGAs in cultured microglia (Bian et 
al., 2008; Kato et al., 2008; Kato et al., 2007). A recent in vivo investigation of the 
effects of risperidone and minocycline (a tetracycline antibiotic known to inhibit 
microglial cell activity) on a developmental cortical lesion animal model 
demonstrated a reduced density of Iba-1 stained cortical microglial cells (Zhu et al., 
2014). The evidence to date suggests an anti-inflammatory role of antipsychotic 
medication, however the in vivo evidence has not produced a comprehensive 
description of morphology or microglial features beyond cell density. It is also 
unclear how antipsychotic medication influences peripheral cytokine levels and how 
this corresponds to density or morphology of cortical microglia. It is also unclear 
how healthy brain tissue and tissue with microglial activity increases would respond 
to the same treatment. These are further questions we aim to address in this thesis.
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Reference  Experimental model Medication Method of assessment Findings  
(Näkki et al., 1996) Ketamine and phencyclidine 
in vivo 
Haloperidol Microglial cell number and 
HSP70 expression 
HSP70 reduced, but microglia were 
unaffected 
(Kowalski et al., 
2003) 
LPS stimulated 
microglia in vitro 
Flupentixol, 
trifluperidol 
TNF-α and NO ELISA Flupentixol and trifluperidol both 
inhibited production of TNF-α and NO 
(Labuzek et al., 
2005) 
LPS stimulated 
microglia in vitro 
Chlorpromazine, 
loxapine 
interleukin-1β (IL-1β) and 
interleukin-2 (IL-2) release 
Both drugs were able to reduce IL-1β 
and IL-2 release 
(Hou et al., 2006) LPS stimulated N9 cells in 
vitro 
Haloperidol, 
Clozapine, 
Olanzepine 
Cell survival and NO production Olanzepine reduced LPS induced NO 
production but Clozapine and 
Haloperidol did not 
(Kato et al., 2007) IFNɣ stimulated 
microglia in vitro 
Risperidone, 
Haloperidol 
Cytokine ELISA and Nitric oxide 
(NO) western blot 
Haloperidol and Risperidone inhibit NO 
production. Risperidone also inhibited 
cytokine production, haloperidol did not 
(Bian et al., 2008) IFNɣ stimulated 6-3 
microglial cell culture in vitro 
Perospirone, 
ziprasidone 
quetiapine 
NO and TNF-α production. Cell 
viability 
All three antipsychotics reduced NO 
production and all but ziprasidone 
reduced TNF-α production. Cell viability 
was not affected. 
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(Kato et al., 2008) IFNɣ stimulated 6-3 
microglial cell culture in vitro 
Aripiprazole 
Quinpirole 
NO production, TNF-α 
production, Ca2+ imaging & cell 
viability 
Aripiprazole reduced NO production, 
but not TNF-α, and Ca2+ concentration. 
Also promoted cell survival. Quinpirole 
did not alter any measures 
(Zheng et al., 2008) LPS stimulated BV2 
microglial culture 
Spiperone NO production, cytokine 
production, NF-κB  
production, cell survival 
Spiperone reduced production of NO, 
cytokines and NF-κB. Cell survival was 
promoted 
(Hu et al., 2011) In vitro LPS stimulated 
microglia/neuronal co-
culture 
Clozapine Microglial immuno- 
histochemistry cell counts 
Clozapine reduced the LPS induced 
microglial cell (Iba-1) count elevations 
(Kato et al., 2011) Phorbol-myristate-acetate 
(PMA)-stimulated 
microglial/neuron co-culture 
in vitro 
Aripiprazole Superoxide production Aripiprazole  reduced PMA induced 
superoxide production and promoted 
neuronal cell survival 
(Seki et al., 2013) IFNɣ stimulated in vitro 
primary microglia and 
oligodendrocyte culture 
Aripiprazole, 
Haloperidol 
Immunoflourescence and 
phagocytosis observation 
Aripiprazole but not haloperidol 
prevented microglial associated 
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inflammatory action and 
oligodendrocyte apoptosis 
(O'Sullivan et al., 
2014) 
In vivo Experimental 
autoimmune encephalitis 
(EAE) and in vitro 
macrophage culture 
Risperidone Cytokine measurement, 
immunohistochemistry of 
microglia/macrophages and 
functional deficit assessment 
Risperidone reduced cytokine 
production, in vivo and in vitro. 
Attenuated physical deficits. Reduces 
quantity of microglia (Iba-1 and CD68) 
in tissue sections 
(Yan et al., 2014) Transient cerebral ischemia 
in vivo 
Risperidone Microglial immuno- 
histochemistry cell counts 
Risperidone reduced microglial 
presence (Iba-1) in CA1 hippocampal 
region 
(Zhao et al., 2014) In vivo Alzheimer’s APP 
transgenic mice 
Quetiapine Microglial immuno- 
histochemistry cell counts 
Quetiapine reduced hippocampal 
microglial cell counts (CD11b) 
(Zhang et al., 2014) In vivo cuprizone induced 
demyelination 
Olanzapine Microglial immuno- 
histochemistry cell counts 
Olanzapine reduced cuprizone induced 
elevations of microglia (CD11b) 
(Zhu et al., 2014) In vivo neonatal 
hippocampal LPS 
Risperidone Microglial immuno- 
histochemistry cell counts 
Risperidone reduced the number of 
microglia (Iba-1) in the cortex 
 
Table 4. Studies of antipsychotic medication and microglia
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18-kDa translocator Protein (TSPO) 
Traditionally named the peripheral benzodiazepine receptor (PBR), TSPO is found 
ubiquitously, but in varying quantity, in the human body and is a protein associated 
with steroid synthesis and transport (Varga et al., 2009). TSPO is an 18 kDa 
structure located on the outer membrane of the mitochondrial matrix and is part of 
a trimeric transmembrane domain and is essential for cholesterol transport (Banati 
et al., 2014). TSPO is expressed in relatively low levels in the mammalian brain. For 
example, tissues rich in mitochondria with a high metabolic and hormonal demand, 
such as the testes and adrenal glands, express a much higher level of TSPO than 
cortical tissue. In the brain, TSPO is found on microglia, astrocytes and certain 
subtypes of neurons, including proliferative neurons in the subventricular zone 
(Varga et al., 2009). 
 
The in vivo functional significance of TSPO has been controversial in recent years 
as the generation of TSPO knockout mice has produced two opposing findings. The 
initial study reported embryonic lethality with a full TSPO knockout (Papadopoulos 
et al., 1997), however the more recent investigation demonstrated how TSPO -/- 
animals were phenotypically normal, with lifespan, growth, cholesterol transport and 
microglial response to injury appearing unaffected. The only deviation from control 
was a reduction in production of adenosine triphosphate (ATP), suggested to be a 
reduction in metabolic activity (Banati et al., 2014). The development of Positron 
Emission Tomography (PET) as an imaging modality has allowed targeting of 
molecular markers in both the healthy and diseased brain, chapter 2 will explore the 
fundamental principles of PET. Ligands binding TSPO are used in PET imaging as 
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a molecular marker of microglia and neuroinflammation. We will cover the details of 
TSPO tracers and their application in chapter 2.  
Translational investigation 
Fundamental neuroscientific questions are being addressed more comprehensively 
as technology progresses to allow for investigation of cellular and molecular events. 
Clinical and basic science have often occurred in isolation of each other, however it 
is useful and informative to investigate questions from both perspectives. While 
many argue that animal models of diseases are not valid as representations of 
disorders, it is possible to model features of diseases to investigate them more 
thoroughly in a whole organism. Nervous system injuries are relatively easy to 
model for a direct comparison to a clinical context. Where diseases of cognition, 
consciousness and perception are the topic of investigation, the situation is less 
clearly defined. In diseases such as Parkinson’s or Alzheimer’s, where there are 
hallmarks of diseases which can be produced in the rodent brain, animal 
investigation of pathology and it’s treatment can greatly inform the clinical context 
and provide greater opportunities for developing therapeutic targets. Psychiatric 
illness is particularly difficult to model for functional deficits as psychiatric disorders 
are diagnosed following structured interview based assessment. While these 
features aren’t assessable in rodent models, the biology underlying the clinical 
features can be modelled to view network and physiological interactions with better 
resolution than available clinically. With these approaches in mind, this thesis will 
address in vivo microglial changes associated with antipsychotic medication. 
Clinical imaging techniques will address microglia in schizophrenia and medication 
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naïve subjects with early signs of psychotic symptoms. Alongside this, animal 
investigation of antipsychotic administration on microglial cell density and 
morphology will serve to further inform the clinical study to determine potential 
consequences of medication in patients with schizophrenia. 
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Aims and outline of thesis. 
 
This thesis aims to answer 3 questions; 
 
1. Is neuroinflammation present prior to the onset of psychosis in UHR subjects 
and patients with chronic schizophrenia? If so, does neuroinflammation relate 
to the severity of symptoms in UHR subjects and patients with schizophrenia? 
2. Is neuroinflammation associated with cortical volume and peripheral 
inflammation in UHR subjects and patients with schizophrenia? 
3. Does antipsychotic drug administration in rats lead to microglial density and 
morphology changes in the cerebral cortex? If apparent, how do these 
associate with peripheral levels of cytokines? 
 
These questions will be answered using the clinical imaging and preclinical 
techniques outlined in the Methods chapter (Chapter 2). The first two experimental 
chapters of this thesis (Chapters 3 and 4) report results from clinical imaging of UHR 
and patients with schizophrenia. Chapter 3 will focus on the PET imaging findings 
and Chapter 4 will relate these to MRI and peripheral inflammatory features. The 
final experimental chapter (Chapters 5) explores the impact of antipsychotic 
medication on microglial cells. Chapter 5, assesses the influence of antipsychotic 
medication on microglial cells and brain volume in vivo. 
Chapter 6 summarizes the key findings of the thesis and discusses the impact of 
such findings on the fields of investigation. The comparison of clinical and animal 
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approaches is also made here. This chapter goes on to discuss the future 
perspectives as well as providing concluding remarks. 
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Chapter 2 – General methods 
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Clinical experimental methods 
Ethics/study approval 
The clinical studies contained in this thesis were approved by the research ethics 
committee at the Hammersmith Hospital, London. The PET study was approved by 
the Administration of Radioactive Substances Advisory Committee (ARSAC), United 
Kingdom. The approval for this study was set up for Imanova imaging centre related 
to the administration of radioactive substances for medical or research purposes. 
The Ionizing Radiation Regulations (1999) provides guidelines on the levels of 
radiation participants can receive and participants were monitored to ensure they 
did not exceed such limits. The patient groups are thoroughly researched, hence we 
ensured participation in this study would not take subjects yearly exposure >10 mSv 
(millisieverts). Whole blood and serum samples from participants were collected and 
stored according to the guidelines of the Human Tissue Act (2004). The clinical study 
was sponsored by King’s College London and the Medical Research Council, 
researcher indemnity was provided by King’s College London. Local research and 
development committees were consulted for participant identification centre (PIC) 
approval. The following trusts were used for PIC: 
South London and Maudsley Mental Health Trust. West London Mental Health Trust 
Central and Northwest London Mental Health Trust. 
Intervention centres and clinical teams used for PIC were given the research 
documents and participants were identified in the team meetings, then approached 
with sanction of the care coordinator. 
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Participants 
Ethical approval was obtained for all clinical experimentation REC: LO/1801 
Clinical cohort recruitment & screening  
 Healthy volunteers were recruited from advertisements in local London newspapers 
(The Metro and Evening Standard) as well as posters on site and in local community 
facilities, such as libraries and general practice clinics. Those who had expressed 
an interest in previous studies were also contacted for participation.  
When a participant had expressed an interest in the study, they were contacted over 
the telephone for an initial screening of basic background information prior to a more 
comprehensive face to face screening interview. In the face to face screening 
interview, informed written consent was taken following an oral and written 
explanation of the study and participation. Participants were encouraged to ask 
questions and given as much time as necessary to decide about participation. 
Following consenting, a psychiatric history was taken and a blood test was taken by 
a clinician to determine the TSPO binding status prior to scanning. Participants were 
remunerated for their travel and time. 
Inclusion criteria  
All subjects were assessed on the following inclusion criteria; 
 All participants will be >18 years old. 
 No significant health contra-indications, other than the conditions of mental 
health being investigated, as determined by a physician. Participants with 
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other health issues are eligible for inclusion if the condition would not 
jeopardize or confound the results or integrity of the study. 
 The subjects must be capable of giving written informed consent, including 
compliance with the statements in the consent form. 
 The subjects must be able to read, comprehend and record written English.  
 A signed, dated written informed consent must be taken 
 
Further to these criteria, patients must have a diagnosis of schizophrenia or 
schizoaffective disorder, as assessed using DSM IV criteria.  
UHR subjects must meet inclusion criteria as assessed with the CAARMS manual 
(Yung et al., 2005). 
 
Exclusion criteria  
All subjects were assessed for the following exclusion criteria; 
 Substance dependence or abuse, including cannabis and alcohol, but not 
nicotine addiction. 
 Benzodiazepine use within 1 month of initial assessment 
 Any form of learning disability 
 Any neurosurgery or neurological disorder, including epilepsy 
 Any serious head injury, resulting in a period of unconsciousness greater than 
1 hour. 
 Any significant cardiovascular disorder, including; 
o Bleeding or clotting disorders such as DVT or CVA 
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o Hypertension – AHA grade II: systolic >160 mm/Hg 
o Arrhythmia or angina 
 Previous treatment with ECT (electroconvulsive therapy) 
 Pregnancy or attempting to conceive 
 Breastfeeding mothers 
 Previous exposure to ionizing radiation that would result in the participant’s 
12 month exposure to exceed 10 mSv following the PET scan 
 MRI contraindications. 
 
Control subjects with a first degree relative diagnosed with an Axis 1 psychiatric 
disorder, or neurodegenerative disorder were also subject to exclusion from this 
study. Current, or past, history of Major Depression or an Axis 1 disorder was also 
an exclusion criterion for healthy volunteers. 
All participants were initially assessed on SCID (structured clinical interview for DSM 
disorders) and DSM-IV sub scales, UHR individuals were further assessed with the 
CAARMS manual and schizophrenic participants with the PANSS. 
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Positron Emission Tomography - principals 
Positron emission tomography (PET) imaging has been used as an experimental 
tool for research and is starting to be applied clinically for the purpose of diagnosis 
and treatment. Tumour identification for surgery is the first branch of PET imaging 
to be applied clinically. The basic principal of PET imaging utilizes gamma radiation 
and half-life decay of radioactive isotopes which are coupled to ligands which bind 
to a receptor or protein of interest. PET is a non-invasive three dimensional imaging 
technique that can be used to investigate the chemistry or molecular biology 
underlying physiological function. The radioligand injected into subjects for imaging 
allow a detailed map of a region or organs marked by the ligand. When a receptor 
or protein in the body is identified for the purpose of research, a corresponding 
ligand can be produced to bind to it. When this ligand has been produced, a 
radioactive species can be combined with the ligand so that when bound in the 
physiological context, gamma radiation can be detected by the PET cameras. 
Detecting the annihilation radiation with this method of imaging, allows a regionally 
specific quantitative level of binding to be determined. PET is a unique way to 
investigate spatiotemporal chemistry and physiology. The question of function often 
arises when evaluating PET evidence. It is difficult to make functional conclusions 
based solely on PET; however in combination with other imaging modalities (such 
as fMRI), a more reliable conclusion can be formed. Isotope production for PET is 
carried out in a cyclotron, near the scan site, as short half-life species used for 
imaging would lose potency if they needed to travel a considerable distance to the 
scanner. A cyclotron is a particle accelerator, which is able to produce isotopes for 
radiochemical coupling by collision of a stable atom with a proton (Spinks, 2000). 
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For an element’s isotope to be compatible with PET, it must emit positrons during 
its half-life decay. Radioactive species with a short half-life decay period are used 
to minimise the harm to participants from the ionizing radiation. Table 5 summarises 
the most commonly used isotopes for PET imaging research (Paans et al., 2002). 
Protons are accelerated in the cyclotron before collision with a stable element. The 
bombardment forces a proton from the neutron of the atom, resulting in the 
production of an isotope with an unstable nucleus. The isotopes undergo 
annihilation, where a positron and neutron are emitted from the nucleus, leaving a 
stable atom in the ligand compound. For example, carbon-11 decays to form stable 
boron-11. The emitted positron combines with an electron and produces two anti-
parallel gamma radiation photons with an energy of 511 keV (Badawi, 1998). This 
gamma radiation is detected by the PET camera and is subsequently used to 
determine the location of the bound isotope through coincidence detection, which 
will be discussed in due course. 
 
Isotope Half life (mins) 
11C 20 
13N 10 
15O 2 
18F 110 
 
Table 5. Common radioisotopes used in PET imaging experiments 
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PET is an in vivo molecular imaging technique with a relatively high resolution with 
many benefits over post-mortem optical imaging techniques. The greatest of these 
advantages is that chemical and molecular changes relating to a specific context 
can be investigated temporally on both an acute timeframe, as well as chronically 
with a longitudinal study design. 
 
PET scanner 
 
The detectors are arranged in a ring in the PET camera and detect the antiparallel 
waves of radiation (Turner and Jones, 2003). The subject lies in the scanner, with 
the target organ (in this case, the brain) centred in the field of view (FOV) (Figure 
5).  
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Figure 5. PET scan schematic 
Schematic of the basic principal of gamma radiation detection in a PET scanner. 
 
The detectors have a scintillator and Photo Multiplier Tubes (PMT) which record 
photon counts. When the photons reach the scintillator, a small flash of light is 
created and is amplified by the PMT, these flashes of light are recorded and used 
for the reconstruction of the dynamic image. Scintillator materials vary, however in 
the studies presented in this thesis a LSO (Lutetium orthosilicate) scintillator 
scanner is used (Spinks, 2000). 
    
Patient 
Detector 
Gamma radiation 
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Coincidence detection 
Detection of the gamma rays occurs simultaneously on either side of the PET 
camera as an annihilation event produces two photon rays which will be detected 
on opposite sides of the detector ring (Spinks, 2000). Hence two events detected 
either side of the ring can be associated with the same annihilation event of the 
bound ligand. A time window for detection provides a coincidence detection 
threshold. If photons reach the detector outside of this temporal threshold they are 
no longer considered for detection. 
PET Image Reconstruction 
These events of detection, also known as count rates, are used as the raw data for 
PET image reconstruction. The scan time is divided into varying groups of timed 
count rates called frames. The initial frames of the scan will cover a shorter period 
of time, where there is a vast amount of activity and a high number of detection 
events. As the injected activity decays, the frames lengthen to capture the less 
frequent events. The dynamic data from the frames are reconstructed into three-
dimensional images through computed post processing. Filtered back project ion or 
iterative reconstruction methods are used to reconstruct the PET image. The 
quantification of reconstructed images gives the distribution of the radiotracer in the 
tissue. Filtered back projection is standard for brain imaging studies. This is because 
it is very accurate from a quantitative point of view, although the visual image 
rendering is relatively poor. Clinical cancer imaging emphasizes visual quality over 
quantitative quality hence there is an emphasis on OSEM like techniques that, with 
a few iterations offer excellent visual rendering. However quantification with OSEM 
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and similar is still dependent on high iteration numbers where signal-to-noise 
degrades rapidly. Unlike the thorax, where areas with high signal are closer to cold 
areas, the brain has generally uniform uptake (ventricles excluded). Evaluation of 
iterative reconstruction and event detection bias (including image render quality, 
signal to noise ratios and image artefacts) is made by (Reilhac et al., 2008).  
 
Blood analysis  
Whole blood (4 mL) was taken from patients before the PET scan, at the time of 
arterial cannulation. Blood was collected in an EDTA impregnated purple top blood 
tube and stored at -80oC until being sent for analysis. (Blood samples were 
analysed by ABS laboratories, UK. As the reagents and equipment needed for 
cytokine analysis were not available on site at the time of experiments). Cytokine 
analysis was conducted by ABS laboratories, Hertfordshire. 
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PET image analysis 
Analysis of the PET data obtained over the time course of the imaging experiment 
is complex. Accurate modelling of the in vivo kinetics largely influences the quality 
of data in this section, we will see the aspects of both tracer and tissue 
compartments which must be accounted for to provide high quality data.  
Tracer kinetics 
The quantified distribution of tracer is a measure of the protein or receptor the tracer 
binds to, in this instance TSPO. The PET tracer is active in a state of equilibrium in 
vivo, where the bound ligand [L+R] and free ligand [L] are able to interact and 
dissociate from the receptors [R] where the net exchange is zero. 
 
     Forward 
  [L]Ligand + [R]Receptor         [L+R]Receptor bound ligand 
     Reverse 
 
When the forward and reverse diffusion equilibrates, the dissociation constant (KD, 
the rate of exchange at equilibrium) can be calculated. 
 
KD = 
 
This measure is a reciprocal representation of the ligand affinity. Hence a High KD 
reflects a low affinity and a low KD reflects a high affinity. The free and bound 
components related to the ligand used for imaging can be used to model tissue 
Concentration of reactants 
Concentration of products 
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distribution of the protein or receptor as we will see in the modelling paragraph, 
using [11C]PBR28 (Rizzo et al., 2014). 
Quantification 
Radio ligand activity is represented by signal from the tissue (in our case the brain) 
and the activity in the blood (the input function). We detect the tissue signal with the 
scintillator, however this does not account for activity in the blood stream. An arterial 
cannula can be placed to derive the input function, however for some tracers, a 
reference region, lacking target receptors, can be used to indirectly calculate the 
input function (Laruelle et al., 2002). In a region of interest model a time activity 
curve for that region is estimated, ultimately providing a representation of tracer 
dose in a volume of tissue (where volume of distribution is used, MBq/cm3 is the unit 
of measure). 
When quantifying the tissue component, factors such as blood flow, vascular 
binding, non-specific target binding and ability to cross the BBB contribute to the 
final tissue activity. Mathematical modelling of these components can make the 
tissue data more accurately reflect receptor distribution (see comparison of 
[11C]PBR28 models, 2TCM and 2TCM-1K and (Turkheimer et al., 2015)). 
Tissue compartment modelling 
This section is limited to ‘reversible’ tracers, with the KD profile discussed so far. 
Tracers such as [11C]PBR28 have a reversible chemical equilibrium and reach this 
state rapidly after injection allowing for a relatively short scan duration (60-90 
minutes), irreversible tracers have a much longer equilibrium time, hence a longer 
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scan duration. Compartmental modelling uses a theoretical model based on the 
known biology of a system to propose an activity cure to fit the data to, providing a 
mathematical representation to conduct analysis with. A tissue compartment is a 
biochemical dimension representing a pool of ligand, which is assumed to be 
homogenous within compartments, however separate compartments can exist in 
the same model with different dynamic properties (Laruelle et al., 2002). For 
receptor binding ligands, four compartments can be defined. The Model appropriate 
for this thesis is the two tissue compartmental model (Figure 6), where the plasma 
concentration of the ligand is one compartment (C1), free ligand and nonspecific 
binding is another compartment and the first tissue compartment (C2) and the 
receptor bound ligand is the third compartment and second tissue compartment 
(C3). 
Plasma   Brain 
 
 
 
 
 
 
 
 
Figure 6. Three compartment, Two tissue compartment model 
The diffusion rate constants K1 (influx), k2 (efflux), k3 (free to specific) and k4 
(specific to free) represent the flow of ligand between compartments, it is possible 
K1 
k2 
k3 
k4 
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to have a third tissue compartment (four compartments total, C4 which models non-
specific binding separately when the proportion is known), where k5 (free to non-
specific) and k6 (non-specific to free) are the rate constants of transfer for that 
compartment.  
In a reference tissue approach, the assumption that the concentrations of free and 
non-specific ligand are homogenous across regions. 
Not all tracers are well enough understood for model fitting to be directly applied to 
PET data (Laruelle et al., 2002). Therefore it is often necessary to study the data 
that has been acquired to derive the correct kinetic components. 
Representations of PET data 
Pet data analysis can be represented by different tissue distributions. Where the 
specific and non-specific components of tracers are known a non-displaceable 
binding potential (BPND) can be calculated. A volume of distribution (VT) is the 
distribution of activity in a volume of tissue. Standardized uptake values (SUV) 
represent a VT normalized by body weight and injected activity. The distribution 
volume ratio (DVR) is a VT normalized by a reference region, this differs from the 
reference region analysis model as the arterial input is still calculated from blood 
data. 
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Neuroinflammation PET tracers 
PET tracers can be produced to bind to known receptors or replace a compound in 
a synthesis pathway. This could be the binding of a specific transmitter to a receptor, 
or the breakdown of a substrate by an enzyme. Similarly in certain situations, where 
a protein, receptor or biological compound is up-regulated, a PET tracer can be 
produced to image the process.  
The focus of this thesis is neuroinflammation and a number of tracers exist with a 
primary purpose of imaging cortical inflammation. The majority of tracers used to 
image inflammation in the brain are based around the TSPO (Translocator protein).  
TSPO is a steroid synthesis protein found on the outer membrane of mitochondria. 
The functional significance of this protein is not widely understood. A single 
nucleotide polymorphism gene mutation affects TSPO in humans. There are three 
forms of the gene, distributed amongst the general population. There are high 
affinity binders with a G/G (Threonine/Threonine) copy, middle affinity binders with 
an A/G copy (Alanine/Threonine) and low affinity binders with an A/A copy 
(Alanine/Alanine); HABs, MABs and LABs respectively (Owen et al., 2011). While to 
some extent this phenomena affects all TSPO imaging, the different ligands in use 
have varying levels of binding, where in some instances low binders do not exhibit 
a decreased signal (Guo et al., 2012). 
PK11195 
This tracer has widely been used for experimental investigation of 
neuroinflammation in a range of clinical disorders, including schizophrenia 
(Doorduin et al., 2009; van Berckel et al., 2008), Parkinson’s (Gerhard et al., 2006), 
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multiple sclerosis (Giannetti et al., 2014; Rissanen et al., 2014), Huntington’s (Politis 
et al., 2011) and Alzheimer’s (Schuitemaker et al., 2013). A high nonspecific binding 
and poor signal-to-noise ratio of PK11195 lead to the development of a new 
generation of TSPO ligands, with an aim to address this issue (Guo et al., 2012). 
Second generation TSPO tracers 
The second generation of TSPO binding radioligands (SGTs) are affected by the 
genetic polymorphism at the rs6971 allele. The development of this new generation 
of ligands aimed to address nonspecificity of PK11195. In an in silico modelling 
study, [18F]PBR111, [11C]PBR28, [11C]DPA713 and [11C]-(R)-PK11195 were 
compared across binding affinities. Within subject variability was reduced in the 
second generation tracers tested, when compared to PK11195 (0.9%-2.2% in SGTs, 
compared to 16%-36% with PK11195). Based on the data from this investigation, 
between-subject studies are predicted to require half the sample of those for 
PK11195 (Guo et al., 2012), Figure 7.  
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Figure 7. Time-activity curves for TSPO tracers  
The three genotypes (HABs, MABs and LABs) across a number of TSPO tracers, including the first generation PK11195. Adapted 
from (Guo et al., 2012).
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Comparison of PK11195 and PBR28 
[11C]PBR28 is a second generation TSPO binding radioligand with a greater 
specificity than PK11195. A growing number of experimental studies have been 
published since its development in 2011 (Guo et al., 2014; Loggia et al., 2015; Owen 
et al., 2014). An in vitro kinetic comparison of PK11195 and PBR28 demonstrates 
how the two binding sites affect the signal of the tracers (Figure 8). PK11195 binding 
was not affected between HABs and LABs (26.4 and 22.3 nmol/L respectively), 
whereas PBR28 was significantly affected by the polymorphism between HABs and 
LABs (3.4 and 188 nmol/L respectively) (Owen et al., 2010). The variation in binding 
affinity is crucial for this [11C]PBR28 study, as our in vivo signal would be dictated 
by the genotype of our subjects. For this reason, subjects undergoing the PBR28 
experimental procedure were screened for binding affinity and LABs were excluded 
prior to experimental procedures. 
  
Figure 8. In vitro binding for TSPO ligands 
HABs, MABs and LABs (blue red black respectively) for PK11195 (A) and PBR28 
(B) in vitro Adapted from (Owen et al., 2010). 
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Experimental procedure for [11C]PBR28 participants 
PET scan Acquisition 
All PET studies were conducted at Imanova, Hammersmith Hospital, London. 
Subjects arrived at least two hours before tracer injection, medical observations 
were performed by the study clinician and an arterial cannula was inserted to the 
radial artery and a contralateral antecubital venous cannula was inserted. All PET 
scans were performed on a Siemens Biograph™ TruePoint™ PET•CT scanner 
(Siemens Medical Systems, Germany). An initial CT scan was performed for 
attenuation and scatter correction (Lercher and Wienhard, 1994).  
[11C]PBR28 synthesis 
The radiotracer [11C]PBR28 (Figure 9) was synthesized as previously described 
(Owen et al., 2014) by reaction of [11C]Methyl Iodide with the desmethyl-PBR28 
precursor.  
 
 
Figure 9. PBR28 compound structure 
Chemical structure of PBR28 from synthesis, adapted from (Wang et al., 2009). 
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 [11C]PBR28 injection 
A bolus of [11C]PBR28 was injected via the venous cannula over 30 seconds by the 
study physician (SS).  
Blood sampling for arterial input function 
Discrete blood samples were manually withdrawn at 5, 10, 15, 20, 25, 30, 40, 50, 
60, 70, 80, 90 minutes, centrifuged and used to determine the plasma over blood 
activity ratio (POB). Samples at 5, 10 and 15 minutes were used to calibrate the two 
sampling modalities. Samples taken at 5, 10, 20, 30, 50, 70 and 90 minutes were 
also analysed using HPLC to calculate the plasma fraction of authentic tracer free 
of metabolites (PPf). Both POB and PPf were fitted with an extended Hill model 
(Edison et al., 2009), while whole blood TACs were fitted using a multi-exponential 
(Tonietto, 2014). For each scan, a time delay was fitted and applied to the input 
functions (both parent and whole blood TACs) to account for any temporal delay 
between blood sample measurement and the target tissue data. 
MRI scans and Regions of Interest (ROI) Definition 
Each subject underwent a T1 weighted MRI brain scan. MRI images were used for 
grey/white matter segmentation and region of interest (ROI) definition. A 
neuroanatomical atlas (Tziortzi et al., 2011) was co-registered on each subject’s 
MRI scan and PET image using a combination of Statistical Parametric Mapping 8 
(http://www.fil.ion.ucl.ac.uk/spm) and FSL (http://www.fsl.fmrib.ox.ac.uk/fsl) 
functions, implemented in MIAKATTM (http://www.imanova.co.uk). The primary 
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region of interest was total grey matter. Secondary regions of interest were temporal 
and frontal lobe grey matter (Radewicz, 2000).  
 a priori ROIs for TSPO assessment: Frontal cortex, temporal lobe and whole 
brain grey matter. 
 Control ROIs for assessment of signal specificity: Cerebellum and brain stem 
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PET Image analysis 
Image analysis  
All PET images were corrected for head movement using nonattenuation-corrected 
images, as they include greater scalp signal, which improves re-alignment 
compared to attenuation-corrected images (Montgomery et al., 2006). Frames were 
realigned to a single ‘reference’ space identified by the individual T1 MRI scan. The 
transformation parameters were then applied to the corresponding attenuation-
corrected PET frames, creating a movement-corrected dynamic image for analysis. 
Regional time-activity curves (TACs) were obtained by sampling the image with the 
coregistered atlas. Hence quantification of [11C]PBR28 tissue distribution was 
performed using the two tissue compartmental model accounting for endothelial 
vascular TSPO binding (2TCM-1K) (Rizzo et al., 2014),  as this has been shown to 
have improved performance compared with the two tissue compartmental model not 
accounting for endothelial binding (2TCM) (Rizzo et al., 2014). Nevertheless, for 
completeness, we analysed the data using the 2TCM as well (Table 11 & Table 12). 
Even after accounting for genotype, high inter-subject variability is seen in imaging 
with TSPO tracers. With PK11195 plasma protein binding is evident and may 
account for some levels of variability with TSPO imaging (Lockhart et al., 2003). 
Indeed TSPO ligand quantification approaches mostly use tissue reference 
methodologies (Turkheimer et al., 2007). Analysis of PK11195 is conducted using 
simplified reference tissue models (SRTM) and supervised cluster analysis (Yaqub 
et al., 2012). This method is not applicable to second generation TSPO tracers, 
including PBR28, as the higher ligand affinity leads to appreciable endothelial 
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binding in the blood brain barrier (BBB) (Rizzo et al., 2014). As a result, it is not 
possible to identify a supervised cluster for reference. Our outcome measure 
therefore was the distribution volume ratio (DVR, the ratio of the 𝑉𝑇 in the ROI to 𝑉𝑇 
in the whole brain) as this accounts for inter-subject variability in the input function. 
In secondary analyses, we tested the regional specificity of group changes by 
comparing DVR between groups in regions (the cerebellum and brainstem) where 
we did not expect marked inflammatory changes based on the post-mortem studies 
and grey matter changes seen in people at risk of psychosis (Wood et al., 2008). 
Comparison of 2TCM and 2TCM-1K performances 
Model fit performance analysis confirmed 2TCM-1K to be superior to 2TCM for 
describing [11C]PBR28 PET data at region level. This finding is consistent with the 
results reported by Rizzo and colleagues applying [11C]PBR28 imaging in a healthy 
population (Rizzo et al., 2014). 2TCM-1K provided a better fit of the tissue data for 
all the analysed ROIs, all the groups of subjects and all the affinities (Figure 10). 
The relative difference of the weighted residual sum of squares obtained with 2TCM-
1K, compared to the 2TCM one, was -55%±25% while the relative difference of the 
residual sum of squares was -50%±30% (mean ± SD). Weighted residuals obtained 
with 2TCM-1K were consistent with the assumptions about the measurement error 
(random and uncorrelated). In terms of parsimony criteria (Akaike, 1974 ), 2TCM-
1K Akaike Information Criterion (AIC)* was smaller than 2TCM AIC in 99.4% of the 
regions, thus confirming the identification of 2TCM-1K as the optimal model to 
describe [11C]PBR28 brain data. In term of outliers the two models performed 
similarly (brain outlier fraction: 3% for 2TCM and 4% for 2TMC-1K). These were 
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concentrated particularly in small regions (average volume <3 cm3), indicating they 
are very likely characterized by high noise data. After correction for outliers, 
individual 𝑉𝑇 estimate precisions were consistent for both models (for 2TCM CV 𝑉𝑇 
= 4%±5%; for 2TCM-1K CV 𝑉𝑇 = 7%±5%). 
 
*AIC is the Akaike Information criterion and it is defined as: 
 
AIC = 𝑛𝐷 ∙ log(𝑊𝑅𝑆𝑆) + 2 ∙ 𝑛𝑃 
 
where 𝑛𝐷 represents the number of data fitted by the model, 𝑊𝑅𝑆𝑆 the weighted 
residual sum of squares and 𝑛𝑃 the number of model parameter.  
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Figure 10. 2TCM and 2TCM-1K fit comparison for [11C]PBR28  
PET data in schizophrenia: application to cortical region in a representative HAB 
subject. The correspondence between the model fit (black line) and measured date 
(red circles) is closer in the 2TCM-1K than the 2TCM model. 
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General experimental methods for animal studies 
Animals 
For all in vivo experimentation, 250g male Sprague Dawley (SD) rats were used 
(Charles River, UK). Animals were randomized into cages, drug administration and 
subsequent post mortem analysis was conducted blindly. Animals were housed in 
individually ventilated cages with food and water ad libitum, with a 12 hour light/dark 
cycle. All experimental procedures were carried out in accordance with the animals 
(scientific procedures) act (ASPA) 1984 and home office regulations. 
Drug delivery Experimental drug administration  
There are a number of techniques routinely used for administering drugs to animals, 
with varying ease of delivery and dose accuracy. In this section, the benefits and 
detriments of the available methods will be discussed.  
Intra-peritoneal  
The most commonly used method of delivery is intra-peritoneal (i.p.) injection. The 
drug is delivered to the peritoneal cavity, where it is absorbed into the bloodstream 
and systemically circulates. The ease of this method has made it the primary 
delivery method in rodent investigations. For single doses i.p. administration is 
certainly a valid and incredibly useful method, however with multiple dose of a drug, 
it is difficult to gain an accurate level of drug, especially if you are aiming to create 
a clinically comparable dose. The metabolism of rodents is far higher than that of a 
human and drugs are broken down at such a high rate that between doses, the drug 
compound is often fully removed from the system. In the past this has caused 
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investigators to used doses far higher than those applicable to the clinic (Kapur et 
al., 2003).  
Oral  
It is possible to give animals drug doses orally, either in drinking water, food sources 
or by gavage. The first two methods are more likely to provide a continual dose of a 
drug, when compared to an i.p. injection, as animals will consume food and water 
throughout the day. However it is not an accurate way of delivering specific doses 
as food and water consumption varies greatly between animals and in cages of 
multiple animals dominance is a significant component in feeding patterns. As well 
as the uncertainty over dose delivery, there is often a chance that the taste of a drug 
will alter the amount of food or water consumed. Many pharmaceuticals have a 
distinctly bitter taste and result in avoidance in the drug dosed group. Gavage has 
similar issues as i.p. administration, where peaks and troughs of administration 
cause a problem for a chronic administration experimental design.  
Subcutaneous delivery  
Subcutaneous delivery methods are relatively new for experimental setups, but 
provide an alternative method of delivery where a number of the issues previously 
mentioned are addressed. Delivery can be via pellets or osmotic mini-pumps. In the 
experiments presented here, animals were anaesthetized using volatile anaesthesia 
(isoflurane, VWR USA) prior to insertion of antipsychotic drug pellets. Animals 
received a low dose (0.05 mg/kg/day (Samaha et al., 2008)) of haloperidol via slow 
release drug pellets (Innovative Research of America, USA). Sterile drug pellets 
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were inserted subcutaneously above the right shoulder blade using a standard 
gauge trochar (Figure 11, Innovative Research of America, USA). The same method 
was implemented for control pellets . 
   
Figure 11. Trochar implantation of pellets 
Subcutaneous drug pellet insertion technique (Images adapted from; Innovative 
Research of America (IRA, USA)). 
Immunohistochemistry 
Animals were transcardially perfused with 4% paraformaldehyde (PFA) and 
postfixed over night at 4oC. Following post-dissection fixation, brains were 
transferred to sucrose solution for cryoprotection (30% sucrose made up in 0.1M 
PBS). Spinal cords were trimmed to cerebellar alignment and olfactory bulbs 
removed prior to weighing and volume calculation. Volumes were calculated using 
water displacement in a finely graduated cylinder (Dorph-Petersen et al., 2005). 
Brain weight was calculated using a top pan balance. Following volumetric and 
weight calculation, the left cerebral hemisphere was embedded in OCT mounting 
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media (CellPath, UK) and frozen using liquid nitrogen for cryosectioning and 
immunohistochemistry.  
Samples were stored at -80oC until cryosectioning (up to 48 hours). Sagittal brain 
slices (25 μm, cut on a Leica cryostat) were thaw mounted on glass superfrost slides 
(VWR, USA) and stored at -20oC until immunohistochemical processing. A standard 
heat mediated antigen retrieval step was implemented prior to staining. Slides were 
outlines with liquid block (Dako, UK) and washed in PBS three times at 5 minute 
intervals. The primary antibody was then applied and incubated over night at 4oC. 
Following incubation with the primary antibody, slides were then washed with the 
same regime of PBS before an hour of incubation with the secondary antibody at 
room temperature for one hour. Following secondary antibody incubation (see Table 
6 for antibody details), slides were washed with PBS and cover slips were mounted 
using Hard-Set VectorshieldTM with an incorporated DAPI stain (Vector laboratories, 
USA). Slides were then stored at 4oC for confocal Imaging.  
 
Antibody Species Concentration Company Catalogue number 
Iba-1 Goat 1/1000 Abcam Ab5076 
Cleaved-
Caspase-3 
Rabbit 1/500 Cell signalling 
technology 
ASP175 
Cy3 Donkey anti-Goat 1/1000 Jackson 705-166-147 
AlexaFluor488 Donkey anti-Rabbit 1/1000 Abcam Ab150073 
 
Table 6. Antibody table 
Antibodies used in this thesis. 
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Image acquisition 
Images were acquired on a Leica SP5 confocal microscope (leica microsystems, 
USA). Sequential scanning was used to provide separation of channels. Z-stacks 
were acquired with a 20x lens to produce a volume made up of 11 planes (Kozlowski 
and Weimer, 2012). The prefrontal cortex was the primary ROI for analysis (Juckel 
et al., 2011). 3 channels were acquired, a low gain CY3, high gain CY3 and DAPI 
nuclear channel. 
Image analysis 
Images were then analysed for cell density and volume density using two analysis 
paradigms. Cell density was calculated using colocalization of nuclear and cellular 
staining with Cell Profiler software (developed for this thesis, details of pipeline and 
modules are found in chapter 5). DAPI nuclei were identified and a 5 pixel proximity 
threshold was set for the colocalization count. The principals of detection were 
adapted from the literature ((Forero et al., 2010; Kozlowski and Weimer, 2012; 
Paolicelli et al., 2011) also see chapter 5). 
Blood analysis  
Two samples of blood (2 mL each) were taken from the animals at the time of 
perfusion (or decapitation in the case of fresh frozen tissue collection). Blood was 
collected in an EDTA impregnated purple top blood tube. One sample was analysed 
for haloperidol levels and the other for peripheral levels of cytokines. (Blood samples 
were analysed by ABS laboratories, UK., as the reagents and equipment needed for 
cytokine and haloperidol analysis were not available on site at the time of 
experiments). 
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Drug delivery analysis 
Levels of haloperidol in the blood of animals were analysed to confirm pellet delivery. 
Haloperidol was quantified in whole rat blood using haloperidol d4 to internally 
standardise the procedure.  Whole blood (100µL aliquot) was subjected to protein 
precipitation using acetonitrile containing the internal standard.  The supernatant 
from the samples was evaporated to dryness under nitrogen and the residue 
reconstituted in 100 µL of 0.05% formic acid.  Aliquots of 10 µL were injected for 
analysis and quantification using high performance liquid chromatography mass 
spectrometry with multiple reaction monitoring (MRM haloperidol m/z 376 to 165 
and haloperidol d4 m/z 380 to 169). The LC-MS/MS system was a CTC DLW 
autosampler, Jasco LC and ABSciex API4000 tandem mass spectrometer. 
Calibration standards containing haloperidol in whole blood plasma were prepared 
in duplicate at 0 (blank), 0.1, 0.25, 0.5, 1.0, 5.0, 10.0, 50.0 and 100.0 ng/mL and the 
samples were analysed with duplicate quality control samples prepared at 0.3, 8 
and 75 ng/mL. Standard FDA (FDA, 2001) and EMA (EMA, 2011) quality 
standards criteria were applied for the acceptance of the analysis batches. 
Cytokine analysis 
For Human and rat whole blood samples, peripheral measures of cytokines (pro- 
and anti- inflammatory) were analysed using a V-PLEXTM multi-spot assay system 
(Mesoscale, USA, the full protocol for the system is available from 
www.mesoscale.com). A list of 10 possible cytokines were available for analysis 
including; IFN-ɣ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13 and TNF--α. The 
figure below (Figure 12) demonstrates the principal of detection; 
Neuroinflammation and psychosis; antipsychotic medication. Peter Bloomfield 
 
91 
 
 
 
Figure 12. Multiplex setup for cytokine detection 
Procedure in human blood (black text and *) and non-human primate blood (black 
text only) (cytokine detection range is the same as human blood for rat samples).  
Whole blood samples were applied to the 96-Well 10-Spot Plate, with two analysis 
runs per sample of blood. Prior to analysis, calibration solutions were run to provide 
detection ranges for the cytokines analysed. 
 
Following collection, samples were frozen until required for the multiplex assay. 
Samples were diluted with a solution containing preservatives and enzyme blockers 
(Diluent 2). 50 µL of the samples, calibration solutions, or control solutions, were 
added to each well. Samples were run in duplicate and average values were 
calculated. Internal controls for human analysis were lyophilized human cytokines 
of known concentrations (3 controls, Mesoscale, USA, catalog # C4049-1). Similarly, 
rat samples were run with lyophilized rat cytokines of known concentrations (3 
controls, Mesoscale, USA, Catalog # C4044-1). Concentration standard curves 
were produced for IFN-ɣ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13 and TNF-
α, alongside experimental samples to confirm detection. The plates were then 
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sealed and incubated at room temperature for 2 hours on an orbital shaker. The 
plate was washed three times using 150 µL of wash buffer per well. 25 µL of 
detection antibody was added to each well and incubated for 2 hours at room 
temperature on a shaker. The plate was washed three times with 150 µL of wash 
buffer per well. 150 µL of reading buffer was added per well before reading on the 
MSD instrument.  
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Statistics 
During experimental design, sample size and power were calculated to ensure 
cohort sizes in both clinical and animal experiments (Jones et al., 2003). Statistical 
analysis was performed using the Statistical Package for the Social Sciences (SPSS 
IBM, USA). For group analysis, an analysis of variance (ANOVA) was conducted, 
with appropriate post hoc tests to exclude type I errors (false positives). Correlation 
statistics were conducted using Pearson’s correlation and a threshold for 
significance in statistical tests was defined at p< 0.05. Data were tested for 
homogeneity of variance using a Levene’s test (Levene, 1960) and in multivariate 
analysis, Wilks Lambda was used to determine F-distribution fit (Wilks, 1938). Data 
are represented as the mean ± standard deviation, unless otherwise stated. Fisher’s 
R-Z transformation was used to conduct group based comparisons of correlative 
analysis (Fisher, 1915). 
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Chapter 3 – Neuroinflammation in UHR and 
schizophrenia. 
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Abstract 
Here we aim to determine whether microglial activity, measured using translocator-
protein positron emission tomographic imaging (PET), is increased in unmedicated 
subjects presenting with pre-clinical symptoms indicating they are at ultra high risk 
of psychosis, and to determine if it is elevated in schizophrenia. We use the second 
generation radioligand [11C]PBR28 and PET to image microglial activity in the brains 
of subjects at ultra high risk for psychosis. Subjects were recruited from early 
intervention centres. We also imaged a cohort of patients with schizophrenia and 
healthy controls for comparison. At screening, subjects were genotyped to account 
for the 18KD translocator-protein polymorphism. The main outcome measure was 
total grey matter [11C]PBR28 binding ratio, representing microglial activity. 
[11C]PBR28 binding ratio in grey matter was elevated in ultra high risk subjects, 
compared to matched controls, (p= 0.004, F= 10.3, Cohen’s d >1.2), and was 
positively correlated with symptom severity (r= 0.730, p< 0.01). Patients with 
schizophrenia also demonstrated elevated microglial activity with respect to 
matched controls (p< 0.001, F= 20.8, Cohen’s d >1.7). Microglial activity is elevated 
in schizophrenia and in subjects with pre-first episode symptoms who are at ultra 
high risk of psychosis. We also show how in the high risk subjects binding is related 
to high risk symptom severity. This indicates that neuroinflammation is linked to the 
risk of psychosis and related disorders, as well as the expression of sub-clinical 
symptoms. Follow up of ultra high risk subjects will determine whether this is specific 
to the later development of schizophrenia or risk factors in general.  
Neuroinflammation and psychosis; antipsychotic medication. Peter Bloomfield 
 
98 
 
Introduction 
 
Schizophrenia is a severe psychiatric disorder characterised by psychotic and 
cognitive symptoms, and is a leading cause of global disease burden (Howes and 
Murray, 2014). It is generally preceded by a prodromal phase of attenuated 
psychotic symptoms and functional impairment (Yung et al., 2005). Subjects 
meeting standardised criteria for this phase have an ultra high risk for developing a 
psychotic disorder, in most cases schizophrenia (Fusar-Poli et al., 2013a). 
Approximately ~35% of high risk subjects will develop a psychotic disorder within 
24 months (Fusar-Poli et al., 2012).  
 
Whilst the pathoaetiology of schizophrenia is not fully understood, there is 
increasing evidence for the involvement of neuroinflammatory processes. Microglia 
are the resident immune cells of the central nervous system and several lines of 
evidence indicate microglial involvement in the pathology of psychosis (Bayer et al., 
1999; Doorduin et al., 2009; van Berckel et al., 2008). In ultra high risk subjects, 
there are elevations in the levels of pro-inflammatory cytokines (Perkins et al., 2014) 
which are also elevated in patients with schizophrenia (Miller et al., 2011). The levels 
of such peripheral markers have also been associated with the reductions in grey 
matter volume in both ultra high risk subjects (Cannon et al., 2014) and patients with 
schizophrenia (Meisenzahl EM, 2001). Post-mortem investigation of brain tissue 
has found elevated microglial cell density (with a hypertrophic morphology) in 
schizophrenia compared with controls (Bayer et al., 1999), particularly in the frontal 
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and temporal lobes (Radewicz, 2000), although some studies have found no 
differences (Steiner et al., 2006). However, as microglial activity is dynamic, post-
mortem studies may miss alterations early in the development of the disease. 
 
Elevations in microglial activity can be measured in vivo with positron emission 
tomography (PET) using radioligands specific for the 18kD translocator-protein 
(TSPO), which is expressed on microglia (Karlstetter et al., 2014). Investigations 
using the first generation radiotracer (R)-[11C]PK11195 have revealed an increase 
in TSPO binding in medicated patients with schizophrenia when compared to 
healthy controls (Doorduin et al., 2009; van Berckel et al., 2008). The first 
investigation of microglia using PET in schizophrenia, in a cohort of 10 patients, 
revealed a total grey matter elevation of microglial activity in the five years following 
diagnosis (van Berckel et al., 2008). The most recent investigation in seven 
chronically medicated patients with schizophrenia using (R)-[11C]PK11195 
demonstrated an elevation in hippocampal binding potential and a non-significant 
30% increase in total grey matter binding potential (Doorduin et al., 2009).   
 
Whilst these studies indicate elevated microglial activity in schizophrenia, they 
included patients in whom the disorder was already established. It is therefore 
unknown whether this elevation predates the onset of, or becomes evident after, the 
first episode of frank psychosis.  
 
Therefore in the present investigation we seek to determine whether microglial 
activity is elevated in ultra high risk subjects using the novel TSPO radioligand 
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[11C]PBR28. Our a priori hypothesis was that microglial activity would be elevated 
in the total grey matter in ultra high risk individuals compared to matched controls. 
An additional prediction was that this elevation would be evident in frontal and 
temporal cortical regions, brain areas that have been particularly implicated in ultra 
high risk pathophysiology (Bose et al., 2008). [11C]PBR28 is a second generation 
TSPO tracer with a higher affinity for TSPO than (R)-[11C]PK11195 (Kreisl et al., 
2010). Recent in situ binding evidence shows that a genetic polymorphism (a C/T 
substitution at rs6971) influences the binding of TSPO tracers, including 
[11C]PBR28. This results in three TSPO binding profiles. High affinity binders (HABs, 
C/C) have the greatest tracer affinity, low affinity binders (LABs, T/T) have a 50 fold 
reduction in affinity, and mixed affinity binders (MABs, C/T) express both HAB and 
LAB TSPO in approximately equal proportion (Owen et al., 2011). In view of this we 
included a cohort of patients to test the hypothesis that TSPO binding is elevated in 
schizophrenia after adjusting for this polymorphism, as this has not been taken into 
account previously. We also tested the secondary hypothesis that there would be a 
positive relationship between total grey matter microglial activity and symptom 
severity. 
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Methods 
 
The study was approved by the local research ethics committee and was conducted 
in accordance with the Declaration of Helsinki. After complete description of the 
study to the subjects, written informed consent was obtained. 
 
Subjects 
A total of 56 subjects were recruited and completed the study; 14 subjects meeting 
ultra high risk criteria, as assessed on the comprehensive assessment of the at risk 
mental state (CAARMS) (Yung et al., 2005), were recruited from OASIS (Outreach 
and Support in South London) (Fusar-Poli et al., 2013b) (Mean age ± SD: 24.3 ± 
5.40; (M:F=7:7)). 14 age matched (± 5 years) control subjects were recruited 
through newspaper and poster adverts. 14 subjects with schizophrenia (Mean age 
± SD: 47.0 ± 9.31; (M:F=12:3)) were recruited from London mental health centres 
(South London and Maudsley NHS Foundation Trust). A further 14 age matched (± 
5 years) healthy control subjects were recruited for comparison with this second 
cohort (Table 7).
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 Control Stdev Ultra high risk Stdev p-value Control Stdev Schizophrenia Stdev p 
 N = 14  N = 14  - N=14  N = 14  - 
Age in years 28.14 7.99 24.29 5.40 0.133a 46.21 13.62 47.00 9.31 0.982a 
Years of education 14.8 3.0 14.3 1.6 0.344a 12.3 3.0 12.2  2.0 0.374a 
Gender (M:F) 10:4  7:7  0.352 b 12:3  12:3  1.000b  
TSPO genotype (HAB) 10  7  0.352 b 14  13  0.541b 
Smoking (cigarettes/day) <1 0.41 3.43 5.56 0.009a 2.15 4.90 12.50 13.69 0.006a 
Alcohol (units/week) 10.78 8.79 6.64 12.89 0.833a 7.13 6.24 9.29  22.22 0.297a 
Drugs of abuse (no. tried) <1 1.05 3.75 2.90 0.003 1.00 1.00 1.29 1.07 0.671a 
CAARMS/ PANSS           
Positive - - 11.2 4.5 - - - 17.0 6.1 - 
Negative - - 6.1 4.3 - - - 14.1 4.0 - 
General - - 19.1 12.3 - - - 32.6 8.7 - 
Total - - 49.5 21.6 - - - 63.7 18.1 - 
Table 7. Demographic characteristics of experimental and control subjects 
 aindependent samples t-test. bMann-Whitney U test. Symptom scales measured in high risk subjects on the CAARMS 
(comprehensive assessment of the ‘at risk mental state’) and in schizophrenia on the PANSS (positive and negat ive syndrome 
scale). 
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Healthy control subjects with a personal history of a psychiatric disorder or a first 
degree relative with schizophrenia or a psychotic illness were excluded. 
 
Clinical and neuropsychological measures 
 
At screening all subjects were assessed using the SCID (Spitzer et al., 1992). Ultra 
high risk subjects were assessed on the CAARMS (Yung et al., 2005) by a trained 
investigator and patients with a diagnosis of schizophrenia were assessed on the 
positive and negative syndrome scale (PANSS) (Kay et al., 1987) by a clinician on 
the day of the PET scan. Depressive symptoms were assessed using the Beck 
Depression Inventory (BDI) (Beck et al., 1961).  
 
PET imaging 
 
An initial computer tomography (CT) scan was acquired for attenuation and scatter 
correction using a Siemens Biograph™ TruePoint™ PET•CT scanner (Siemens 
Medical Systems, Germany). Subjects then received a bolus injection of [11C]PBR28 
(mean Mbq activity ±SD: 325.31 ± 27.03) followed by a 90-minute emission scan. 
PET data were co-registered with whole brain structural images acquired with a 3T 
magnetic resonance imaging (MRI) scanner (Trio, Siemens Medical Systems, 
Germany). A 32 channel coil was used for all but one scan, where a 12 channel coil 
was used instead.  
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PET acquisition 
PET data were acquired dynamically over a 90-minute time window and binned into 
26 frames (durations: 8 x 15 s, 3 x 1 min, 5 x 2 min, 5 x 5 min, 5 x 10 min). Images 
were reconstructed using filtered back projection, which provides better data quality 
and signal-to-noise ratio over iterative methods (Reilhac et al., 2008), and corrected 
for attenuation and scatter. During the PET acquisition, arterial blood data were 
sampled via the radial artery using a combined automatic-manual approach. A 
continuous (one sample per second) sampling system (ABSS Allogg, Mariefred, 
Sweden) measured whole blood activity for the first 15 minutes of each scan.  
Structural MRI 
Each subject underwent a T1 weighted MRI brain scan. MRI images were used for 
grey/white matter segmentation and region of interest (ROI) definition. A 
neuroanatomical atlas (Tziortzi et al., 2011) was co-registered on each subject’s 
MRI scan and PET image using a combination of Statistical Parametric Mapping 8 
(http://www.fil.ion.ucl.ac.uk/spm) and FSL (http://www.fsl.fmrib.ox.ac.uk/fsl) 
functions, implemented in MIAKATTM (http://www.imanova.co.uk). The primary 
region of interest was total grey matter. Secondary regions of interest were temporal 
and frontal lobe grey matter (Radewicz, 2000).  
Statistical analysis 
Data, other than for gender and genotype, were shown to have a normal distribution 
following a Shapiro-Wilk test (Shapiro, 1965). Hence parametric tests were 
implemented for all but gender and affinity analyses, where a Mann-Whitney U test 
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was used. Demographic data and tracer activity data were analysed using 
independent-samples t-tests. Multiple analysis of covariance (ANCOVA) with 
Bonferroni correction (Dunn, 1961) was used to determine whether there was an 
effect of group on [11C]PBR28 binding associated microglial activity in the total grey 
matter, frontal lobe, and temporal lobe. There is data to suggest that cortical 
microglial density, hence TSPO binding, is elevated with aging (Schuitemaker et al., 
2012), which is also evident in our data (Table 8). For this reason, we performed 
group level analysis using age as a covariate. TSPO genotype was also included as 
a co-variate in analysis as there is a significantly higher binding of tracer in HABs 
than MABs (Owen et al., 2011). For all statistical comparisons alpha was set at a 
0.05 threshold (two-tailed) for significance. Statistical analysis was performed using 
SPSS 21 (IBM, USA). Partial correlation analysis was used to test the association 
of microglial activity with symptom severity and total grey matter volumes, with age 
and affinity as covariates of no interest.  
Measure r statistic p value 
Total grey matter Vt 0.336 0.016* 
Frontal lobe Vt 0.368 0.008** 
Temporal lobe Vt 0.329 0.018* 
Frontal lobe DVR 0.307 0.032* 
 
Table 8. Age correlations  
(Pearson’s two-way product moment correlation coefficient) with volume of 
distribution (Vt) and distribution volume ratios (DVR) Pearson’s correlation (two-
way, *p<0.05; **p<0.01).  
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Results 
Demographic Comparisons and Tracer Dosing 
No significant demographic differences between the two groups of controls and 
respective patient groups were observed (Table 7). There were no differences in the 
injected dose, injected mass, specific activity, parent plasma fraction or plasma over 
blood ratio between ultra high risk subjects or patients with schizophrenia and their 
respective controls (Table 9). 
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 Control 
(SD) 
Ultra 
high risk 
(SD) 
pa Control 
(SD) 
Schizophrenia 
(SD) 
pa 
Injected dose 
(MBq) 
326.6 
(26.6) 
327.6 
(26.7) 
 
0.982 
326.3 
(25.5) 
318.9 
(33.8) 
 
0.910 
Injected mass 
(µg) 
2.8 
(1.3) 
3.4 
(2.1) 
 
0.390 
2.5 
(0.8) 
2.5 
(1.1) 
 
0.905 
Specific activity 
(GBq/µmol) 
49.3 
(22.1) 
43.4 
(21.4) 
 
0.418 
50.0 
(18.4) 
52.7 
(20.9) 
 
0.981 
Parent plasma 
fraction (%) 
8.5 
(2.1) 
9.9 
(3.5) 
 
0.376 
12.0 
(3.6) 
12.7 
(3.0) 
 
0.635 
POB (ratio) 0.0034 
(0.0017) 
0.0033 
(0.0013) 
 
0.667 
0.0039 
(0.001) 
0.0044 
(0.002) 
 
0.511 
Table 9. Scan Parameters for [11C]PBR28 
aindependent samples t-tests. 
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[11C]PBR28 distribution in total grey matter regions 
The [11C]PBR28  distribution volume ratios in total grey matter, frontal lobe and 
temporal lobe grey matter were significantly increased in ultra high risk when 
compared with matched control subjects (Figure 13 A and Table 10).  Similarly, 
patients with a diagnosis of schizophrenia had elevated [11C]PBR28 DVRs in total, 
frontal lobe and temporal lobe grey matter with respect to matched control subjects 
(Figure 13 B and Table 10). Secondary analysis to investigate regional specificity 
revealed no difference between ultra high risk or schizophrenia and respective 
controls in cerebellar or brainstem DVR (Table 10). Representative PET images of 
control, ultra high risk and patients with schizophrenia are presented in Figure 13 
C. When comparing regions using Vt, with either 2TCM or 2TCM-1K, no significant 
group difference was observed (Table 11 & Table 12). 
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Mean Regional 
DVR of 
[11C]PBR28 
Control SD Ultra high 
risk 
SD F P Cohen’s d Control SD Schizophrenia SD F p Cohen’s d 
Total grey Matter 2.032  0.017 2.088  0.021 10.332 0.004 1.244 2.465  0.020 2.557  0.014 20.802 <0.001 1.769 
Frontal lobe 2.000 0.038 2.087  0.026 5.339 0.030 0.894 2.489  0.037 2.606  0.025 9.883 0.005 1.245 
Temporal lobe 1.914  0.041 2.001  0.028 4.417 0.047 0.829 2.282  0.065 2.518  0.044 13.089 0.001 1.430 
Cerebellum  2.307  0.055 2.287  0.081 0.062 0.805 - 2.863  0.060 2.873  0.063 0.015 0.905 - 
Brain stem 2.291 0.191 2.489 0.28 0.500 0.487 - 2.514 0.154 2.097 0.234 3.194 0.088 - 
 
Table 10. Microglial activity in UHR and schizophrenia 
Microglial activity, as measured by PBR28 distribution volume ratio, is elevated in subjects at ultra high risk of psychosis (df=21 
p=0.004) and patients with schizophrenia (df=21 p<0.001) in the total grey matter, frontal and temporal cortical regions of interest 
but not in control regions (the cerebellum and brainstem). The mean regional distribution volume ratios are shown for each group 
together with those for matched controls. The results of the ANCOVA covarying for age and translocator -protein genotype are 
shown for each case-matched control comparison. 
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Regional DVR of [11C]PBR28 Control (SD) UHR (SD) p Control (SD) Schizophrenia (SD) p 
Total grey Matter 4.169 (0.010) 4.204 (0.015) 0.031* 4.676 (0.015) 4.738 (0.011) 0.001# 
Frontal lobe 4.093 (0.029) 4.140 (0.043) 0.290 4.623 (0.050) 4.682 (0.034) 0.024* 
Temporal lobe 4.230 (0.041) 4.225 (0.061) 0.940 4.807 (0.047) 4.693 (0.033) 0.256 
 
Table 11. [11C]PBR28 Distribution volume ratios (DVR) 
Microglial activity, as measured by PBR28 distribution volume ratio with a 2TCM analysis, is elevated in subjects at ultra high risk 
of psychosis (df=21 p=0.031) and patients with schizophrenia (df=21 p=0.001). The mean regional distribution volume ratios are 
shown for each group together with those for matched controls. The results of the ANCOVA covarying for age and translocator -
protein genotype are shown for each case-matched control comparison (*p<0.05; #p<0.01). 
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Regional VT of [11C]PBR28 (2TCM) Control (SD) UHR (SD) P Control (SD) Schizophrenia (SD) p 
Total grey Matter 4.444 (0.245) 3.929 (0.357) 0.162 4.925 (0.348) 4.488 (0.502) 0.393 
Frontal lobe 4.362 (0.242) 3.870 (0.352) 0.175 4.867 (0.342) 4.437 (0.494) 0.762 
Temporal lobe 4.493 (0.238) 3.962 (0.346) 0.138 5.055 (0.404) 4.445 (0.501) 0.691 
Regional VT of [11C]PBR28 (2TCM-1K)       
Total grey Matter 2.145 (0.157) 1.975 (0.228) 0.461 2.740 (0.210) 2.361 (0.306) 0.228 
Frontal lobe 2.113 (0.158) 1.974 (0.230) 0.551 2.764 (0.212) 2.406 (0.310) 0.260 
Temporal lobe 2.019 (0.148) 1.896 (0.215) 0.569 2.543 (0.207) 2.322 (0.302) 0.471 
 
Table 12. [11C]PBR28 Distribution volumes (VT)  
Microglial activity, here measured by PBR28 VT with a 2TCM and 2TCM-1K analysis, did not differ between groups (UHR df=21 
p>0.05; Schizophrenia df=21 p>0.05). The mean regional VTs are shown for each group together with those for matched controls. 
The results of the ANCOVA covarying for age and translocator-protein genotype are shown for each case-matched control 
comparison.
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Antipsychotic medication 
Two subjects in the ultra high risk group had taken citalopram in the past. However 
only one was using the medication at the time of scan, and no other UHR subjects 
had taken psychotropic drugs. Re-analysis excluding the two subjects who had 
taken citalopram did not alter the significant elevation in [11C]PBR28 DVR in the high 
risk group in the total (F=6.601, p=0.018) and frontal lobe (F=5.392, p=0.030) grey 
matter but the finding in the temporal cortex was no longer significant (p=0.149). All 
but one Patient with schizophrenia were taking medication at the time of scan. 
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Figure 13. Microglial activity measured with PET 
Data and representative scans from ultra high risk subjects, patients with 
schizophrenia and matched controls Significant difference between experimental 
(red) and control (blue) groups, ANCOVA (covarying for age and genotype). A, a 
(df=21 p=0.004). b (df=21 p=0.030). c (df=21 p=0.047). B, d (df=21 p<0.001). e 
(df=21 p=0.005). f (df=21 p=0.001). C, representative [11C]PBR28 PET images from 
subject groups. 
  
A 
B 
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Relationship between [11C]PBR28 distribution and symptom severity 
 
In ultra high risk subjects, there was a positive correlation between the total 
CAARMS symptom severity score and [11C]PBR28 DVR in total grey matter (r = 
0.730, p = 0.011, Figure 14). No correlation was observed between [11C]PBR28 DVR 
in total grey matter and duration of ultra high risk symptoms (r= -0.086, p= 0.802). 
In patients with schizophrenia, there was no significant correlation between total 
grey matter DVR and total PANSS score (Figure 15). There was no relationship 
between depressive symptom severity (Beck Depression Inventory score) and total 
grey matter DVR in either patients with schizophrenia (r= 0.478 p= 0.162) or ultra 
high risk subjects (r=-0.339 p= 0.506).  
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Figure 14. Microglial activity and symptoms in UHR subjects 
Significant correlation between measures. Partial correlation including age and 
genotype as covariates (N=13, data were missing for 1 subject r= 0.730, p= 0.011). 
Highlighted subject, transition case. 
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Figure 15. Microglial activity and symptoms in schizophrenia  
Total grey matter [11C]PBR28 distribution volume ratios were not significantly 
correlated with symptoms in patients with schizophrenia (r= 0.538, p= 0.071), 
measured on the positive and negative syndrome scale (PANSS). 
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Exploratory analysis of DVR normalization 
To evaluate whether our findings were influenced by the signal used for 
normalization, we conducted exploratory analyses using the cerebellum and white 
matter as alternative normalization regions. Cerebellar normalization did not alter 
the major regional findings (frontal lobe p=0.001; temporal lobe p=0.006). White 
matter normalization performed similarly to the cerebellum (Table 13). 
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Region of interest Normalization region Control (SD) Schizophrenia (SD) p 
Frontal lobe- grey matter     
 Cerebellum 2.345 (0.100) 2.710 (0.070) 0.001# 
 White matter 2.400 (0.111) 2.695 (0.074) 0.014* 
Temporal lobe- grey matter     
 Cerebellum 2.232 (0.120) 2.599 (0.084) 0.006# 
 White matter 2.208 (0.145) 2.592 (0.096) 0.015* 
 
Table 13. Exploratory analysis of the region used for normalization  
[11C]PBR28 DVR in frontal and temporal grey matter regions for varying normalisation regions. The results of the ANCOVA 
covarying for age and translocator-protein genotype are shown for each case-control comparison (*p<0.05; #p<0.01). Significant 
regional elevations of microglial activity, as measured by PBR28 distribution volume ratio, are seen in pat ients with schizophrenia 
when using cerebellar and white matter normalization approaches, consistent with the findings with the whole brain normalizat ion. 
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Discussion 
Our main finding is that [11C]PBR28 binding ratio, a marker of microglial activity, is 
elevated in people at ultra high risk of psychosis, with a large effect size (Cohen’s d 
>1.2). Furthermore [11C]PBR28 binding ratio was associated with the severity of 
symptoms in ultra high risk subjects, linking elevated microglial activity to the 
expression of sub-clinical psychotic symptoms. Importantly we found no relationship 
with depressive symptoms, suggesting elevated microglial activity is specific to the 
development of psychotic-like symptoms, rather than psychiatric symptoms in 
general. It would be valuable to examine change in [11C]PBR28 signal during the 
course of the prodromal period to determine if there is a change during the 
prodromal phase. As the ultra high risk subjects, who had recently presented to 
psychiatric services, were medication naïve and had no history of psychotic 
disorder, these findings cannot be attributed to effects of previous illness or its 
treatment. Interestingly, at the time of writing, one ultra high risk subject has 
transitioned to first episode psychosis. This subject had the highest total grey matter 
[11C]PBR28 signal in the cohort (DVR=2.14). Follow up of the remaining subjects is 
required to determine the role of elevated TSPO availability in the onset of 
psychosis. 
The present findings are consistent with recent evidence of elevated peripheral 
inflammatory markers in people at high risk of psychosis (Cannon et al., 2014; 
Perkins et al., 2014), and suggest that elevated microglial activity predates the onset 
of frank psychosis. We also found evidence of elevated microglia activity in people 
with schizophrenia relative to controls with a large effect size (Cohen’s d >1.7). This 
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extends previous PET studies which have not controlled for TSPO genotype 
(Takano et al., 2010), a potential confound as genotype influences binding, by 
showing that TSPO binding is elevated after controlling for TSPO genotype. Our 
findings are also consistent with the findings of a post-mortem study in 
schizophrenia, which also used PBR28. However, because it was in vitro, was able 
to use a two-point assay to quantify specific PBR28 binding to show elevated PBR28 
binding in schizophrenia (Kreisl et al., 2013). We did not find the same symptom 
correlation in schizophrenia as we did in ultra high risk subjects. This may be due 
to the fact that these patients were not acutely unwell. 
Limitations 
Antipsychotic treatment is a potential confound in the schizophrenia group but not 
the ultra high risk group. There is growing evidence to suggest an influence of 
antipsychotic medication on microglial cell dynamics, including evidence that 
antipsychotics may reduce microglial activity (Kato et al., 2007; Seki et al., 2013; 
Zhu et al., 2014). Hence in future studies it would be preferable to investigate 
patients with schizophrenia who were medication naïve.  
In this investigation, we have used an approach to analysis (accounting for 
endothelial and vascular binding), which has been shown to be more reliable than 
alternative approaches (Rizzo et al., 2014). This was applied in a standardized 
automated manner across groups, and also applied to control regions (brain stem 
and cerebellum) to examine the specificity for our findings. A limitation of all current 
approaches to imaging microglia, including with [11C]PBR28, is that the outcome 
measure is Vt. Thus the elevation in grey matter could reflect increased non-specific 
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tracer binding as well as biological signal. However, blocking studies have shown 
that a substantial proportion of Vt for [11C]PBR28 is specific binding to the TSPO 
(Owen et al., 2014), although the proportion in schizophrenia remains to be 
determined. We used the distribution volume ratio (DVR), in this case with whole 
brain signal as our normalization region, as our outcome measure. We also showed 
that the main findings remained significant when other regions were used, 
suggesting that the findings are robust to the method of normalization. The use of 
DVR analysis is a standard approach in PET imaging that has recently been applied 
to second generation TSPO tracers (Coughlin et al., 2014; Dimber et al., 2014), 
including using whole brain normalization (Loggia et al., 2015), as well as to the first 
generation TSPO tracer PK11195 (Arias, 2014; Rissanen et al., 2014). Preclinical 
studies have demonstrated that the DVR approach is able to detect microglial 
changes due to inflammatory stimuli and confirmed that elevated DVR signal 
corresponds to elevated levels of TSPO and other markers of microglia measured 
ex vivo using immunohistochemistry and/or autoradiography (Converse et al., 2011; 
Imaizumi et al., 2007; Maeda et al., 2011; Martín et al., 2010). These preclinical 
studies thus indicate the functional significance of elevated [11C]PBR28 DVR and 
support further in vivo investigation in patients. 
Large regions of analysis were used as the primary outcome measure in this 
chapter. The choice of whole brain grey matter was based on the changes reported 
in the literature with the first generation ligand PK11195. Further to this we selected 
the frontal and temporal lobes for analysis as these are regions which demonstrate 
the greatest volume changes through the course of the disease. At the time if writing, 
analysis methods, including voxelwise analysis of PBR28 are still in development. 
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Hence while sub regions were calculated in analysis, large regions were chosen for 
this thesis, where signal could be more reliably quantified, over smaller voxels which 
are more susceptible to noise and artefacts. 
Interpretation of the DVR using the whole brain signal for normalization is 
complicated as it includes grey matter signal as well. The exploratory analysis using 
white matter signal for normalization showed an elevation in total grey matter signal, 
which was greater in absolute terms than that seen when whole brain signal was 
used for normalization. This suggests that there may be a relative reduction in white 
matter TSPO signal in schizophrenia. Taken with our regionally specific elevations 
in frontal and temporal cortices, these findings are consistent with a re-distribution 
of microglia from white matter and other brain regions to grey matter in frontal and 
temporal cortices, in line with findings after cortical injury (Lloyd-Burton et al., 2013). 
However, a longitudinal study is required to determine whether this interpretation is 
correct.  
The normalization approach would likely account for global group differences in non-
specific binding but we cannot exclude a grey matter selective increase in non-
specific binding contributing to the elevations seen. Whilst the signal-to-noise ratio 
of [11C]PBR28 PET imaging is better relative to first generation tracers, it remains 
relatively low. However this noise would obscure a difference between groups, so is 
unlikely to account for our findings. In this study we did not correct for possible 
partial volume effects. Given that brain volume is generally reduced in 
schizophrenia, these would tend to underestimate the elevations observed here and 
not account for our group differences. There is a relatively higher binding in control 
subjects matched to patients with schizophrenia over those matched to the ultra 
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high risk group. This can be explained in part by age associated increases in TSPO 
but also by an increased number of MABs in the ultra high risk matched controls. 
Finally, it is important to note that not all the ultra high risk subjects will go on to 
develop a psychotic disorder and we will conduct clinical follow-up to determine 
whether the elevated microglial activity is specific to the development of the disorder 
or risk factors for psychosis.  
Implications 
Whilst TSPO may be expressed on astrocytes (Martin et al., 2009) and some 
neuronal sub-types (Varga et al., 2009), it is predominantly expressed on microglia 
(Taylor and Sansing, 2013). The direct biological relationship between microglia and 
TSPO binding in vivo is not fully understood. However, in non-human primates 
inflammation induced increases in microglial activity cause marked increases in 
[11C]PBR28 signal, confirmed post mortem to be largely due to microglial binding 
(Hannestad et al., 2012). Microglia perform immune surveillance roles, mount 
inflammatory response to injury (Kettenmann et al., 2011) and are involved in 
synaptic modulation in experience dependent plasticity (Tremblay et al., 2010). 
Interpretation of elevated activity is therefore complex and not defined by ‘activated’ 
or ‘resting’. The elevations presented here might reflect a protective response 
triggered by associated pathology, such as glutamatergic excitotoxicity (Howes et 
al., 2015) or indicate a primary neuroinflammatory process linked to risk factors for 
psychosis and the development of sub-clinical symptoms. When biological data (e.g. 
PET) and symptoms (e.g. CAARMS or PANSS) are being assessed, longitudinal 
investigation is particularly useful for interpreting the relationship of the measures. 
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If the two demonstrate corresponding fluctuations over time it provides further 
evidence for inter-related processes. TSPO PET has been demonstrated to vary 
quite considerably in healthy volunteers, with PBR28 test retest variation being 
between 13-26% with a 2-5 day interval (Collste et al., 2015). Similarly, psychotic 
symptoms change over time with transition rates being the highest in the first 2 years 
from presentation to psychiatric services, with symptoms reaching threshold for 
psychosis in 25% of individuals at 1 year and 35% at the 2 year time point (Cannon 
et al., 2008). To date there has not been a comprehensive investigation of symptom 
variability during this prodromal stage. 
 When our findings are interpreted with evidence that anti-inflammatory drugs are 
effective in schizophrenia (Müller, 2002), particularly in addressing early negative 
symptoms (Chaudhry et al., 2012), they suggest a neuroinflammatory process is 
involved in the development of psychotic disorders. Whilst this indicates that anti-
inflammatory treatment may be effective in preventing the onset of the disorder, 
further studies are required to determine the clinical significance of elevated 
microglial activity. 
 
Conclusions 
Here we provide, to our knowledge, the first evidence of elevated brain microglial 
activity in people at ultra high risk of psychosis, and show that greater microglial 
activity is associated with greater symptom severity. We also demonstrate the first 
in vivo elevations of TSPO binding in schizophrenia with a second generation tracer 
after adjusting for TSPO genotyping. These findings are consistent with increasing 
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evidence that that there is a neuroinflammatory component in the development of 
psychotic disorders, raising the possibility that it plays a role in its pathogenesis. 
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Chapter 4 – TSPO, cytokines and MRI 
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Abstract 
Patients with schizophrenia and subjects at ultra-high risk for psychosis (UHR) have 
reduced cortical grey matter volumes, UHR subjects who transition to psychosis 
also have a more rapid rate of grey matter volume reduction. Patients and UHR 
subjects also demonstrate higher concentrations of pro-inflammatory cytokines in 
peripheral blood. In the previous chapter we have seen how patients and UHR 
subjects have elevated levels of microglial activity. It is unclear how peripheral 
cytokine levels, volumetric brain changes and microglial activity relate, if at all. In 
this study we investigate patients, UHR subjects and matched controls to determine 
whether cytokine levels, cortical volumes and cortical microglial activity are 
associated.  
Subjects received an [11C]PBR28 PET scan and a structural MRI scan. Peripheral 
blood, from the time of the PET scan, was analysed for levels of pro-inflammatory 
cytokines. Correlation analysis was performed to determine whether relationships 
between measures were apparent. 
Patients and UHR subjects consistently exhibited higher levels of inflammatory 
cytokines, however these levels only reached significance with TNF--α (p= 0.018 
and p= 0.013 for UHR and schizophrenia respectively). Patients with schizophrenia 
had a reduced cortical volume compared to both control and UHR subjects (p= 
0.004 & p= 0.025, respectively). Peripheral levels of TNF--α, IL-6, IL-1β, IL-10 and 
IFNɣ did not correlate with cortical volumes or [11C]PBR28 signal in matched regions 
of interest. Cortical volumes were not correlated with [11C]PBR28 binding in UHR, 
schizophrenia or control groups.  
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Introduction  
Cortical grey matter loss is associated with a conversion from high clinical risk to 
first episode psychosis (Pantelis et al., 2003b; Wood et al., 2008). Progressive grey 
matter detriments are also seen following the first episode of psychosis (Bose et al., 
2009; McGlashan and Hoffman, 2000; Ortiz-Gil et al., 2011; Sandu et al., 2008). In 
schizophrenia, a reduction in grey matter volume is associated with antipsychotic 
administration (Fusar-Poli et al., 2013c; Radua et al., 2012), which is also seen in 
animals treated with antipsychotics ((Dorph-Petersen et al., 2005; Vernon et al., 
2011) See chapter 6). The exact cause of this reduction is unclear. 
Peripheral inflammatory cytokine levels (including IFNɣ, TNF--α, IL-1β, IL-2, IL-6 
and IL-10) are also associated with the progressive loss of grey matter in UHR 
subjects and the onset of first episode psychosis, where higher levels of pro-
inflammatory cytokines relate to a higher probability of transition (Cannon et al., 
2014; Perkins et al., 2014). Patients with schizophrenia have elevated levels of 
peripheral cytokines, independent of medication status (Miller et al., 2011). In 
particular, peripheral levels of the inflammatory cytokine interleukin 6 (IL-6) were 
found to be elevated in patients with schizophrenia when compared to control 
subjects (Nunes et al., 2006). Recent investigations of inflammatory markers IL-6 
and c-reactive protein have revealed an association between childhood serum 
levels and the incidence of depression and psychosis in young adult life (Khandaker 
et al., 2014). Pro-inflammatory cytokines are released by microglial cells in states 
of inflammatory stress and in response to tissue damage (Kettenmann et al., 2011). 
A severe state of systemic inflammation in animals produces reactive microglia 
centrally, alongside elevated levels of peripheral cytokines (Cunningham, 2013). 
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Microglia are also known to be responsive to signalling proteins when involved in 
plasticity events involving synaptic reorganisation (Parkhurst et al., 2013; Tremblay 
et al., 2010). 
Schizophrenia is associated with greater binding of TSPO radiotracers, thought to 
reflect elevated levels of microglial activity (Doorduin et al., 2009; van Berckel et al., 
2008). In the previous chapter, we have seen how this is evident with the novel PET 
tracer [11C]PBR28 in patients with schizophrenia, as well as UHR subjects compared 
to matched controls. 
It is currently unclear whether cortical volume changes, peripheral cytokine levels 
and cortical microglial activity are associated in patients with schizophrenia or UHR 
subjects. In the previous chapter we have seen how symptoms associate with 
[11C]PBR28 binding in UHR, here we analyse peripheral cytokine levels as well as 
cortical grey matter volumes alongside TSPO PET signal ([11C]PBR28) to determine 
whether these peripheral and cortical parameters are related to psychosis.  
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Methods  
The study was approved by the local research ethics committee and was conducted 
in accordance with the Declaration of Helsinki. After complete description of the 
study to the subjects, written informed consent was obtained. 
Participants 
A total of 35 subjects were recruited and completed this multimodal imaging study; 
13 subjects meeting UHR criteria, as assessed on the comprehensive assessment 
of the at risk mental state (CAARMS) (Yung et al., 2005), were recruited from OASIS 
(Outreach and Support in South London) (Fusar-Poli et al., 2013b) (Mean age ± SD: 
24.38 ± 5.61; (M:F=6:7)). 11 subjects with schizophrenia (Mean age ± SD: 43.64 ± 
10.8; (M:F=9:2)) were recruited from London mental health centres (South London 
and Maudsley NHS Foundation Trust). 8 healthy control subjects were recruited for 
comparison (Table 14).
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 Control Ultra high risk Schizophrenia p 
N= 8 13 11  
Age (mean(±sd)) 27.00 (7.73) 24.38 (5.61) 43.64 (10.82) <0.001 
Genotype (MAB:HAB) 2:6 7:6 2:9 0.279 
Sex (M:F) 4:4 6:7 2:9 0.162 
Total symptoms (mean (±sd)) - 46.18 (20.02) 64.36 (15.46) - 
 
Table 14. Demographic characteristics of subjects  
Patients with schizophrenia were significantly older than both control subjects and UHR subjects (Symptom measures for UHR 
and schizophrenia are measured on the CAARMS and PANSS respectively). 
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Correlations between total grey matter volume & TSPO signal 
Brain volumes, [11C]PBR28 signal and peripheral inflammatory measures were 
analysed for correlation. Regions of interest were defined by the results from 
chapter 3, where whole brain grey matter, frontal and temporal lobe regions were 
found to be elevated in case groups. Respective MRI volumes were extracted as 
structural data for correlative analysis. 
MRI and PET registration 
Each subject underwent a T1 weighted MRI brain scan. MRI images were used for 
grey/white matter segmentation and region of interest (ROI) definition. A 
neuroanatomical atlas (Tziortzi et al., 2011) was co-registered on each subject’s 
MRI scan and PET image using a combination of Statistical Parametric Mapping 8 
(http://www.fil.ion.ucl.ac.uk/spm) and FSL (http://www.fsl.fmrib.ox.ac.uk/fsl) 
functions, implemented in MIAKATTM (http://www.imanova.co.uk). The primary 
region of interest was whole brain grey matter. Secondary regions of interest were 
temporal and frontal lobe grey matter (Radewicz, 2000).  
MRI analysis methods 
MRI volumes were analysed using the “FreeSurfer image analysis suite”, which is 
an open source analysis suite available for download online 
(http://surfer.nmr.mgh.harvard.edu/). The methods of analysis are previously 
published and have been used extensively (Reuter et al. 2012). Images were 
processed in the FreeSurfer longitudinal stream to produce volume estimates 
(Reuter et al., 2012). Skull stripping, Talairach transformations, atlas registration as 
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well as spherical surface maps and parcellations are applied after a within-subject 
template. 
PET acquisition and analysis 
PET acquisition and analysis was performed as outlined in chapters 2 & 3 of this 
thesis. 
Cytokine analysis 
Cytokine analysis was performed using a multiplex system (Mesoscale Discovery, 
USA), as described in the general methods in chapter 2. 
Statistical analysis 
DVRs were created using the methods described in chapters 2 & 3, where whole 
brain PET signal was used to provide a normalization for regional signal. Group 
differences were assessed using an ANOVA with a Tukey’s post hoc comparison. 
Spearman’s rho correlation (two-way) was implemented for correlation of PET, MRI 
and blood data. We used Spearman’s over Pearson’s here as it is less influenced 
by outliers (Kornbrot, 2005), which may present an issue with the smaller cohort 
sizes in this chapter. Data were analysed using SPSS 21 (IBM, USA). 
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Results 
Demographic variations 
There is an age difference between the three groups (p< 0.001), where the patients 
with schizophrenia are significantly older than both controls and UHR subjects. 
Unfortunately we were unable to obtain peripheral inflammatory measures and both 
scan types for all subjects, which prevented us from having two individually matched 
control cohorts as in chapter 3. Hence age was factored in as a covariate of analysis. 
The demographics of the groups are outlined in Table 14. 
Cortical volume analysis 
Consistent with the literature, there were significant total grey matter volume 
reductions in patients with schizophrenia when compared to control subjects as well 
as UHR subjects (p= 0.004, p= 0.025 respectively, Figure 16). There was no 
difference between UHR and control subjects (p> 0.05). Temporal and frontal lobe 
volumes were not significantly different between groups. 
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Figure 16. Total grey matter volumes 
Total grey matter volume reductions were present in patients with schizophrenia 
when compared with both control and UHR subjects. Volumes did not differ between 
UHR and control subjects. 
 
Symptoms and Volume 
There was no correlation between symptom score and cortical volumes in UHR or 
patients with schizophrenia (rho= 0.305 p= 0.310; rho= -0.142 p= 0.677, 
respectively). Total grey matter volume and symptom correlations are presented in 
Figure 17.
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Figure 17. Total grey matter volumes and symptom correlations 
There was no correlation between the volumes of total grey matter and symptom scores on the CAARMS or PANSS in UHR (A) 
and patients with schizophrenia (B) respectively.  
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Medication and volume 
The literature suggests medication impacts cortical volume. In patients with 
schizophrenia, we see a correlation between the chlorpromazine equivalent dose of 
medication and total grey matter volume (rho= -0.674 p= 0.023, Figure 18). 
 
 
 
Figure 18. Medication doses and volume correlation in schizophrenia  
The volume of total grey matter in the brains of patients with schizophrenia was 
negatively correlated with the level of chlorpromazine equivalent doses of 
medication.  
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Correlations between total grey matter volume & TSPO signal 
There was no correlation between the levels of [11C]PBR28 binding in whole brain 
grey matter and the volume of total grey matter across any of the groups (p> 0.05, 
Figure 19). There was no correlation between temporal or frontal lobe [11C]PBR28 
binding and respective volumes in any of the participant groups (data not shown).  
 
 
Figure 19. Correlation plots for total grey volume and whole brain grey DVR  
Volumes and [11C]PBR28 DVR were not correlated in control subjects (A), UHR 
subjects (B) or patients with schizophrenia (C). With statistical summary table (D).   
Group Total grey matter volume/Whole 
brain grey matter DVR correlation 
Control Rho=-0.095 p=0.823 
UHR Rho=0.181 p=0.553 
Schizophrenia Rho=-0.455 p=0.160 
A B 
C D 
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Cytokine analysis 
Here we were not able to perform analysis of cytokines for all subjects that we had 
imaging data from (a number of subjects did not produce adequate amounts of blood 
for analysis). When the full cohort of subjects with blood data were included, 11 
control, 11 UHR and 13 patients with schizophrenia could be analysed for peripheral 
blood markers. In this instance, both the UHR and schizophrenia groups 
demonstrated elevated levels of TNF--α when compared to control (p= 0.018 and 
p= 0.013 respectively, Figure 20). All other cytokines were numerically elevated in 
experimental groups, however TNF--α was the only statistically significant elevation. 
Of the peripheral cytokines only IL-10 correlated with the level of cortical 
inflammation using a DVR but not VT approach (Table 15). Cytokines did not 
correlate with total grey matter volumes. 
 
Figure 20. Whole blood TNF-α levels in patients and controls 
Peripheral levels of TNF-α were elevated in both UHR subjects and patients with 
schizophrenia when compared to healthy control subjects. 
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Cytokine Grey matter DVR Grey matter VT Total grey matter volume 
TNF--α Rho=-0.277 p=0.191  Rho= -0.364 p=0.081 Rho=-0.292 p=0.166 
IL-6 Rho=-0.067 p=0.749 Rho=0.136 p=0.518 Rho=0.000 p=0.998 
IL-1β Rho=-0.104 p=0.621 Rho=0.020 p=0.926 Rho=0.128 p=0.543 
IL-10 Rho=0.396 p=0.05 Rho=0.345 p=0.091 Rho=-0.276 p=0.197 
IFNƔ Rho=-0.114 p=0.588 Rho=-0.012 p=0.953 Rho=0.048 p=0.819 
 
Table 15.  Microglial and inflammatory marker correlation analysis  
Correlation statistic and p values for all subject analysis of [11C]PBR28 signal (DVR, 
VT & MRI volume) and peripheral blood cytokine concentration. Of the cytokines 
tested only IL-10 was associated with central measures of inflammation.  
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Discussion 
In this study, we have demonstrated a reduction in total grey matter volume in 
patients with schizophrenia compared to control and UHR subjects. Interestingly, 
while numerically lower, the total grey matter volumes of UHR subjects was not 
significantly lower than control subjects. Patients with schizophrenia exhibited a 
reduction in total grey matter volume when compared to control and UHR, however 
no correlation between volume and [11C]PBR28 binding was present. Average levels 
of peripheral cytokines were higher in UHR subjects and patients with 
schizophrenia, however only TNF--α reached statistical significance. The anti-
inflammatory cytokine IL-10 was negatively correlated with the level of whole brain 
grey matter [11C]PBR28 binding, however it is unclear how this relates as it is an 
association present when all subjects are combined. 
As discussed in the previous chapter, partial volume correction should be 
implemented for accuracy in PET data. However, in this instance partial volume 
correction has not yet been applied to [11C]PBR28 data, due to the methodological 
complexities with this novel tracer. 
There is a significant reduction in total grey matter volume in patients with 
schizophrenia compared to control and UHR subjects. While age is a confound in 
this context, the patients in this investigation were also taking antipsychotic 
medication. When we compared equivalent medication dose with cortical volume, 
we saw a relationship in patients with schizophrenia. This correlation may be a 
consequence of disease duration and severity, as subjects at a later stage of 
disease exhibit greater reductions in volume (Fusar-Poli et al., 2013c; van Haren et 
al., 2008), however literature on this topic suggests medication alone produces 
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cortical volume reductions (Dorph-Petersen et al., 2005; Fusar-Poli et al., 2013c; 
Radua et al., 2012; Vernon et al., 2011). We included age as a covariate of analysis 
to help minimise the effect of age on brain volume. Chapter 6 will further address 
the implications of antipsychotic medication on brain volume, as well as the 
presence of microglia in the cortex.  
Implications 
This investigation is, to our knowledge, the first dual cohort multi-modality study of 
cortical inflammation (TSPO), peripheral inflammation (cytokine levels) and cortical 
volume in schizophrenia and UHR subjects. 
Follow up of UHR subjects will be useful to determine whether cortical changes 
progress as in patients with schizophrenia. The results in this section suggest 
medication is a greater influence than psychotic-like symptoms for cortical volume 
loss. The animal literature suggests volumetric loss is influenced strongly by 
medication (Dorph-Petersen et al., 2005; Vernon et al., 2014; Vernon et al., 2011), 
however longitudinal study shows withdrawal of medication allows recovery of 
volumetric deficits in animals (Vernon et al., 2011). It would be interesting to know 
whether antipsychotic withdrawal in patients would have a similar effect on brain 
volume recovery. It would also be interesting to determine whether subjects 
discharged from psychiatric services return to a control subject level of TNF--α in 
the blood stream.  
While we have investigated volume and [11C]PBR28 correlations it would also be 
useful to analyse cognitive function to see how activity of cortical microglia may 
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associate with cognition. This could be done using fMRI, with tasks relating to 
executive function or working memory.  
Limitations 
This investigation is limited by the number of subjects we managed to obtain all 
measures for, subsequently the statistical power for analysis is low and does not 
provide a comprehensive assessment of relationships between parameters. Where 
the number of subjects is low, as in this experiment, data analysis is affected greatly 
by Type I & II statistical errors, where falsely positive or negative results occur due 
to insufficient statistical power (Banerjee et al., 2009). These correlation analyses 
were exploratory in nature and will form the basis of future experiments on this topic. 
In the previous chapter, we discussed the influence of age on TSPO and [11C]PBR28 
binding. The literature suggests that age is associated with cortical volume 
reductions and ventricular enlargement (Ge et al., 2002). In our cohorts, the subjects 
with the lowest cortical volumes are the patients with schizophrenia. The patients 
are also older than the control and UHR populations. Unfortunately we were not able 
to analyse all the control subjects analysed in chapter 3 for brain volumes and 
cytokines to provide the same two evenly matched control groups as used for 
analysis in the previous chapter. In the future we will be able to assess the structural 
MRI from these participants for appropriately age matched cohorts. 
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Conclusion 
In this investigation we have determined that the cortical volume reduction seen in 
patients with schizophrenia is not correlated with levels of microglial activity. Further 
to this we see elevated levels of the peripheral inflammatory marker TNF--α, in both 
UHR subjects and patients with schizophrenia. Elevated TNF-α levels are not 
associated with elevated TSPO tracer binding or cortical volume alteration. 
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Chapter 5 – Haloperidol LPS microglia. 
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Abstract 
Microglia are restricted to the central nervous system, they provide innate immunity 
and are also involved in synaptic turnover. In chapter 3 we have seen how microglial 
activity is elevated in association with the early stages of psychosis, as well as in 
patients with chronic schizophrenia receiving antipsychotic medication. In chapter 4 
we have seen reductions in cortical volume in chronically medicated patients with 
schizophrenia. At present it is unclear how psychosis and antipsychotic medication 
interact in terms of microglia density or morphology and cortical volumes. Here we 
administer haloperidol, a first generation antipsychotic with a predominantly 
Dopamine receptor D2 (DRD2) occupancy, to naïve and lipopolysaccharide 
(LPS)/saline control treated groups of Sprague Dawley rats to test the effects on 
animals exposed to no stimulus and an inflammatory stimulus respectively. We aim 
to discover potential alterations in cortical volume and microglial cell density and 
morphology in vivo. We demonstrate that in naïve and LPS dosed animals microglial 
cell density and morphology is not altered by haloperidol administration. In naïve 
animals, haloperidol treatment resulted in a reduction in whole brain volume, which 
was absent in LPS/saline treated groups. These findings suggest  haloperidol is not 
associated with microglial cell changes.  
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Introduction 
Clinical imaging modalities provide an insight to the ways in which neurochemistry 
is altered in patients, as demonstrated with positron emission tomography (PET). 
Cognitive changes in patients cohorts can be investigated using fMRI (functional 
Magnetic Resonance Imaging) and structural deficits can be revealed with MRI. 
Cortical structure and chemistry in patients can be investigated both with respect to 
healthy controls (cross sectional) and over time against a baseline scan 
(longitudinal). While the progression of disease symptoms can be followed over 
time, it is not possible to determine which changes in patients are medication related 
and which are purely a consequence of disease progression (Cannon et al., 2015; 
Dorph-Petersen et al., 2005; van Haren et al., 2008). In chapter 3 we saw how 
medicated patients with schizophrenia had an elevated level of microglial activity 
compared to matched healthy controls. We also saw elevated microglial activity in 
un-medicated subjects at ultra high-risk for psychosis (UHR). The level of microglial 
associated signal was relatively higher in medicated patients, but it is unclear how 
medication influences this. While progression of disease and age effects 
(Schuitemaker et al., 2012) may be the cause of this elevation, medication may 
serve to exacerbate or attenuate these levels. 
Animal models of schizophrenia are commonly investigated experimentally (Jones 
et al., 2011; Juckel et al., 2011; Taylor, 2009) and the efficacies of antipsychotic 
drugs are assessed with behavioural (Zhu et al., 2014), electrophysiological (Kato 
et al., 2008) and histological techniques (Juckel et al., 2011). Reduction of disease 
model associated behavioural deficits are often the primary outcome measure. Until 
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relatively recently, drug effects had not been investigated in vivo without the 
influence a disease model. 
A number of studies investigating the influence of antipsychotic medication on 
cortical volumes have demonstrated drug associated reductions in both whole brain 
and regional analysis (Dorph-Petersen et al., 2005; Vernon et al., 2014; Vernon et 
al., 2011). Similarly, investigation of antipsychotic effects using PET have been 
conducted to look at the effects of antipsychotic treatment on post-synaptic enzyme 
activity (Natesan et al., 2014). There is a growing body of literature investigating the 
effects of antipsychotic drugs on different brain cells, including microglia. A range of 
experiments have been conducted by the Kanba laboratory in Japan to investigate 
the effects of antipsychotic medication on microglial cells (Bian et al., 2008; Kato et 
al., 2008; Kato et al., 2007). We saw in chapter 1 that the findings of these 
experiments demonstrate decreases in inflammatory action of microglial cells in 
many contexts. A number of studies observed changes with second generation 
antipsychotics, but not first generation drugs. These results come from isolated 
microglial populations in vitro (see introductory chapter 1) and often use a high dose 
of antipsychotic drug, when compared to a clinical context. The doses of haloperidol 
in the literature can be over 2mg/kg, inducing catalepsy and leading to a receptor 
occupancy far higher than applicable to the clinic (Kapur et al., 2003). In vivo models 
of traumatic brain injury (TBI) and multiple sclerosis have investigated antipsychotic 
medication for the attenuation of functional impairment. Functional improvements 
and reduced numbers of CNS macrophages and microglia were observed with 
risperidone in a mouse model of MS (O'Sullivan et al., 2014). However in the TBI 
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study a functional deficit was exacerbated by the highest dose of haloperidol 
(0.3mg/kg), no immunohistochemistry was performed (Wilson, 2003).  
A single investigation of risperidone in an inflammatory lesion model of 
schizophrenia has been conducted in vivo. The study demonstrated a reduction in 
the density of microglial cells, however quantification of cellular morphology (soma 
size, branch length, stain intensity) were not included (Zhu et al., 2014).  
Microglial cell morphology and density can be diverse. The mechanisms and 
functions related to these cellular morphologies are largely uncharacterised. 
Changes in cell density are believed to occur through the proliferation or apoptosis 
of quiescent cells (Gómez-Nicola et al., 2013). The interruption of the cell cycle can 
inhibit proliferation and reduce production of proinflammatory cytokines (Koguchi et 
al., 2003; Zhang et al., 2009). 
 
In this investigation we administered haloperidol continuously to naïve and 
systemically inflamed rats to address the following hypotheses, using the software 
cell profiler software (see appendix 1); 
Main hypothesis: 
Haloperidol reduces microglial density and morphological complexity. 
Secondary hypotheses: 
Reduction in cell numbers associated with haloperidol is due to increased amounts 
of microglial apoptosis. 
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Methods 
Animals 
Male Sprague Dawley (SD) rats were randomised into cages and acclimatised for 1 
week prior to the start of drug dosing. Animals were housed in a 12h light/dark cycle 
at 21oC, with food and water ad libitum and in accordance of the home office 
regulations outlined in the animals in scientific procedures act (A(SP)A, 1964).  
Experiments were conducted by PSB, with blinding of drug administration 
conducted by Federico Grillo, Graham Little, Lucien West and Katerina 
Popadopoulou. After tissue processing and slide preparation, PSB was further 
blinded to slide number by the previous individuals. 
Drug dosing 
Haloperidol was administered using chronic slow release subcutaneous drug pellets 
(0.05 mg/kg for 2 weeks, Innovative Research of America, USA). Two experiments 
were conducted, in experiment 1 we sought to determine whether haloperidol 
treatment (n=11) had brain (volume mass or density) or microglial associated effects 
when compared to placebo controls (n=18).The dose of haloperidol was calculated 
to provide a ~40-50% receptor occupancy to make findings more applicable to a 
clinical context (Kapur et al., 2003). Continuous delivery is preferable to i.p. 
administration as it removes peak and trough doses, which are not comparable to 
the metabolic profile of patient medication (Bédard et al., 2011; Kapur et al., 2003). 
In experiment 2, LPS was administered i.p. over two weeks with four doses (1mg/kg 
n=13 LPS+placebo, n=7 LPS+haloperidol) LPS, sigma Aldrich, USA) this was to 
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provide a chronic state of systemic and cortical inflammation. Acute LPS produces 
a robust inflammatory response peaking between 8 and 24 hours (Buttini et al., 
1996). However we were seeking a more chronic regime producing the hypertrophic 
chronically inflamed morphology seen in post-mortem schizophrenia (Bayer et al., 
1999; Steiner et al., 2006). We selected the 4x doses at 1 mg/kg regime based on 
(Chen et al., 2012), producing a reactive morphology (Figure 21), over 2 weeks. 
 
Figure 21. Chronic LPS regimen cortical microglial morphology 
Adapted from (Chen et al., 2012), scale bar = 60 µm. 
 
Control animals were dosed with saline (i.p. 4x over 2 weeks, Saline/placebo n=5, 
Saline/haloperidol n=4) and placebo pellets were inserted. Haloperidol was 
measured in the bloodstream of animals as outlined in the general methods (chapter 
2). 
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Cerebral morphology 
Cerebral mass and volume were assessed using a top pan balance and fine 
graduated cylinder, where water displacement was used to determine cerebral 
volume (Dorph-Petersen et al., 2005). Density was calculated using the equation; 
 
density =    
 
Immunohistochemistry 
Tissue was processed as described in the general methods for histological 
assessment. 
Confocal image acquisition 
Images were acquired on a Leica SP5 confocal microscope as described in chapter 
2. 
Generation of maximum projections 
Maximum intensity projections (MIPs) were created from image stacks for 
automated analysis. These were processed using a batch script implemented in Fiji 
(Fiji Is Just ImageJ, NIH, USA) for each image set. Following generation of MIPs, 
image folders were imported to Cell Profiler for automated quantification. 
  
mass 
volume 
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Confocal image acquisition 
For acquisition see Appendix 1. 
Image analysis  
Microglial cell analysis was conducted using the cell profiler and Fiji skeleton 
analysis (Morrison and Filosa, 2013) as outlined in Appendix 1, Figure 22 shows the 
acquisition and analysis as a schematic. For apoptosis analysis, DAPI nuclei were 
substituted with a caspase-3 channel. 
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Figure 22. Pipeline summary schematic 
Schematic flow diagram with a simplified sequence of analysis steps.
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Statistical analysis 
Data were analysed in SPSS, for group statistics an ANOVA with a Tukey’s posthoc 
test was performed. Alpha was set as a p< 0.05 threshold for significance. 
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Results 
Due to the two experimental contexts in this section, results figures with be 
presented as part A (placebo vs haloperidol pellets) and part B (saline/placebo vs 
LPS/placebo vs LPS/haloperidol, vs saline/haloperidol). 
 
Administration of antipsychotic medication via subcutaneous drug pellets resulted 
in a low level of plasma haloperidol in pellet treated animals (mean ± SD 0.23 ng/mL 
± 0.12). No haloperidol was detected in placebo pellet dosed animals. Body weight 
was not different across experimental conditions (see Table 16). LPS dosed animals 
exhibited piloerection and nasal/ocular discharge. No severe adverse side effects 
were observed in any groups. 
 
Group Mean body weight SD 
Placebo 379.61 24.85 
Haloperidol 369.30 23.14 
Saline/placebo 348.20 26.45 
LPS/placebo 347.92 22.21 
LPS/haloperidol 345.38 21.26 
Saline/haloperidol 345.00 1.95 
 
Table 16. Animal body weight 
Endpoint body weights for experimentally dosed animals (mean ± SD), placebo 
n=18, haloperidol n= 11, saline/placebo n=5, LPS/placebo n=13, LPS/haloperidol, 
n=7, saline/haloperidol n=4. P>0.05 ANOVA). 
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The dose regime used was relatively low, hence was not expected to cause 
extrapyramidal side effects or catalepsy. For this reason, vacuous chewing 
movements were not assessed. 
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Brain morphology  
In animals treated with haloperidol there was a reduction in brain volume compared 
to placebo (placebo, mean ± SD 1.931 cm3 ± 0.210; haloperidol, 1.546cm3 ± 0.292 
*p = 0.014, effect size= 0.226, -19.9%, 24A). In LPS, saline and haloperidol 
treatment groups there was no change in brain volume (p> 0.05 figure 24B). Total 
brain mass was not altered in any treatment conditions (p> 0.05). When mass and 
volume were combined to provide density, haloperidol treated animals exhibited a 
relative elevation in cerebral density compared to control (placebo compared to 
haloperidol p= 0.022). 
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Figure 23. Brain mass, volume and density 
(A) Brain mass was not altered with haloperidol treatment, brain volume was 
reduced (p= 0.014) and cerebral density was elevated (p= 0.022)  in animals treated 
with haloperidol (n=11) when compared with placebo dosed counterparts (n=18) 
mean values ± SD. (B) In saline/placebo n=5, LPS/placebo n=13, LPS/haloperidol, 
n=7 and saline/haloperidol n=4 dosed animals, there were no differences in brain 
volume mass nor density (p> 0.05). Mean values ± SD.  
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Microglial cell measures 
The parameters of assessment developed in Appendix 1 were used for microscopy 
analysis in this chapter. 
Cell density 
Haloperidol treatment did not alter microglial density when compared with placebo 
controls (mean ± SD; 106.57 ± 35.38, 107.56 ± 19.65; n= 11, 18 respectively, p> 
0.05, Figure 25A). Administration of LPS did not result in an elevation of microglial 
cell density compared to saline controls (mean ± SD for saline/placebo = 90.53 ± 
31.41, LPS = 98.96 ± 31.82 p> 0.05 figure 25B), haloperidol treatment did not alter 
the density of cells in any experimental condition (p> 0.05). 
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Figure 24. Microglial cell density quantification 
(A) Microglial cell densities were not altered with haloperidol (n=11) treatment 
compared to placebo (n=18) (p= >0.05 ANOVA). Mean values ± SD. (B) In 
saline/placebo n=5, LPS/placebo n=13, LPS/haloperidol, n=7 and saline/haloperidol 
n=4 dosed animals, there was no difference in microglial cell densities (p> 0.05 
ANOVA). Mean values ± SD. 
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Soma area 
Soma size was not altered in either naïve (Figure 25A, p> 0.05) or LPS/Saline 
(Figure 25B, p> 0.05) conditions. 
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Figure 25. Microglial soma size quantification 
(A) Microglial soma sizes were not altered with haloperidol (n=11) treatment 
compared to placebo (n=18) (p> 0.05) mean values ± SD. (B) In saline/placebo n=5, 
LPS/placebo n=13, LPS/haloperidol, n=7 and saline/haloperidol n=4 dosed animals, 
there was no difference in microglial cell densities (p> 0.05). Mean values ± SD.  
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Soma intensity 
Haloperidol treatment did not alter microglial density when compared with placebo 
controls (Figure 26A, n= 11, 18 respectively, p> 0.05). Administration of LPS did not 
result in an elevation of microglial cell density compared to saline controls (p> 0.05), 
haloperidol treatment did not alter the density of cells in any experimental condition 
(p> 0.05 Figure 26B). 
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Figure 26. Microglial soma stain intensity 
(A) The average Iba-1 intensity (AU) of the cell body was not altered with haloperidol 
(n=11) treatment compared to placebo (n=18) (p> 0.05) mean values ± SD. (B) In 
saline/placebo n=5, LPS/placebo n=13, LPS/haloperidol, n=7 and saline/haloperidol 
n=4 dosed animals, there was no difference in soma intensity (p> 0.05). Mean 
values ± SD. 
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Skeleton morphology 
Haloperidol did not alter average branch lengths compared to placebo dosed 
animals (p> 0.05,). LPS did not alter branch morphology compared to Saline 
controls (p> 0.05) Error! Reference source not found., C-F, demonstrates a 
epresentative field of view from each experimental group, due to age of tissue, 
background intensity of staining obscured processes for quantification with this 
approach, subsequently n= is lower than in previous analysis approaches where 
bacground was less of a problem for quantification. 
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Figure 27. Process morphology analysis 
(A) Branch lengths were not altered with haloperidol (n=3) treatment compared to 
placebo (n=8) (p> 0.05) mean values ± SD. (B) In saline/placebo n=5, LPS/placebo 
n=13, LPS/haloperidol, n=7 and saline/haloperidol n=4 dosed animals, there was 
no difference in microglial branch morphology (p> 0.05). Mean values ± error bars 
Iba-1 
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= SD. Microglial staining from the groups: placebo (C) haloperidol (D) saline/placebo 
(E) LPS/placebo (F) LPS/haloperidol (G) saline/haloperidol (H) scale bar = 100µm. 
 
Nuclear counts 
The numbers of total cell nuclei were not altered in haloperidol (n=11) treated 
animals compared to placebo (n=18, p> 0.05). Similarly in LPS/Saline dosed groups 
there was no difference in cortical nuclei (saline/placebo n=5, LPS/placebo n=13, 
LPS/haloperidol, n=7 and saline/haloperidol n=4, p> 0.05, figure 28B).  
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Figure 28. Total nuclear counts 
(A) The average number of DAPI stained nuclei was not altered with haloperidol 
(n=11) treatment compared to placebo (n=18) (p> 0.05) mean values ± SD. (B) In 
saline/placebo n=5, LPS/placebo n=13, LPS/haloperidol, n=7 and saline/haloperidol 
n=4 dosed animals, there was no difference in numbers of nuclei (p> 0.05). Mean 
values ± SD.
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Apoptotic cells 
Analysis of caspase-3 a marker of apoptotic cell death (Burguillos et al., 2011) was 
used to determine whether numbers of microglia in the different groups were 
sustained with different rates of turnover. There was no difference between total 
numbers of caspase-3 positive cells or caspase-3 positive microglial cells between 
groups (p>0.05 figure 29).  
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Figure 29. Apoptotic cell and nuclear counts 
Numbers of apoptotic nuclei and apoptotic microglia were not altered by either LPS or haloperidol treatments (p>0.05). 
Representative images of microglia and apoptotic nuclei (Iba-1 (red) and caspase3 (green) respectively. Scale bar = 50 µm) for 
saline/placebo (n=5) A, LPS/placebo (n=7) B, LPS/haloperidol (n=6) C and saline/haloperidol (n=6) D treated groups. Graphical 
representation of numbers of apoptotic microglia E and total apoptotic cells F. 
E 
F 
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Discussion 
In this chapter we have seen that haloperidol does not alter microglial cell densities 
across a range of treatments. We saw a reduction in cerebral volume with 
haloperidol treatment when compared to placebo dosed controls. Our LPS regimen 
did not produce the desired response seen in (Chen et al., 2012).  
In this investigation, we see a cerebral volume reduction in our haloperidol treated 
animals compared to placebo controls (~20%). This reduction is not apparent with 
the LPS and saline treatments. This reduction is comparable to that seen in patients 
with early onset schizophrenia after the first five years of treatment (Thompson et 
al., 2001), as well as previous animal experiments using a high dose and different 
time courses of regime (Dorph-Petersen et al., 2005; Vernon et al., 2014; Vernon et 
al., 2011). The percentage difference in volume is greater in our investigation than 
in the Dorph-Petersen and Vernon studies. This may be a result of the low resolution 
of discrimination we have in our modality compared to the use of larger primate 
brains (Dorph-Petersen et al., 2005) and MRI (Vernon et al., 2011). 
Further clinical studies expanding on this have demonstrated cortical loss in 
schizophrenia and UHR subjects (Bose et al., 2009; Ortiz-Gil et al., 2011; Pantelis 
et al., 2003a; Sandu et al., 2008; Walterfang et al., 2008). This raises the possibility 
that cortical reductions may be attributed, at least in part, to the medication used to 
treat the disorder. Indeed in chapter 4 we demonstrate cortical volume reductions in 
medicated patients with schizophrenia, but not the unmedicated UHR subjects. The 
present replication of previous findings is reassuring in terms of drug delivery and 
cortical consequences of administration. We did not see a reduction in the total 
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number of cells present across the groups. With a reduced volume, but a preserved 
cell number, it is unclear where the volume reduction is taking place. It is speculated 
that psychotropic medication associated volume loss may arise due to a reduction 
in synapse number (Moorhead et al., 2007; Tost et al., 2010) however further 
investigation is needed to determine the cause of the loss we see. 
Previous research has demonstrated how, antipsychotic medication is able to 
reduce a range of inflammatory actions of microglial cells in vitro (Bian et al., 2008; 
Kato et al., 2008; Kato et al., 2007; Kato et al., 2011; Kowalski et al., 2003; Labuzek 
et al., 2005; Seki et al., 2013). However, a number of these studies report conflicting 
results and it is not clear how the in vitro models relate to the whole brain. A recent 
study using a neonatal lesion model of schizophrenia revealed a reduction in 
microglial cell density in vivo (Zhu et al., 2014). The analysis in this investigation 
was limited to manual cell counting and had a primary focus on behavioural deficits, 
as well as using a relatively high dose of medication. A recent investigation of 
haloperidol in rats, using a high continuous dose of haloperidol demonstrated an 
elevation in numbers of activated microglial cells (Cotel et al., 2015). The 
inconsistencies in findings across the varying studies from in vivo to in vitro suggest 
that there are subtleties to the interaction of microglial cells and antipsychotic 
medication. For example, the (Cotel et al., 2015) study uses higher doses of 
medication and in vitro studies have different time courses in isolated microglial 
preparations, where cell-cell type interactions existing in vivo are not present. 
 
The staining of apoptosis using caspase3 does not correspond with reports in the 
literature (Burguillos et al., 2011). Staining was initially tested in control and LPS 
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treated tissue and a secondary antibody only staining was performed to determine 
specificity of stain signal. In a control condition few apoptotic cells should be 
present, whereas we see many positive nuclei (50-60 positive nuclei per ROI). This 
suggests that the antibody is not specific for activated caspase-3 and binding to 
both active and inactive forms. To determine how accurate the staining is, it would 
be useful to confirm these stainings using TUNEL (Kyrylkova et al., 2012) and Fluoro 
jade B (Schmued and Hopkins, 2000) approaches. 
Future investigation 
There are 2 largely open questions at the end of this chapter; 
1. What underlies the reduction in brain volume following haloperidol 
administration? 
Psychotropic medication is hypothesised to reduce brain volume through synaptic 
remodelling (Tost et al., 2010). To address this I will perform western blots to quantify 
the amount of synaptic proteins following haloperidol. 
2. Why did LPS not result in the same changes in cell density reported by (Chen 
et al., 2012)?  
The Chen study delivered LPS on consecutive days, whereas our doses were 
spread over two weeks. This may be responsible for a lack of visible response in 
our experiments. Animals were lightly anaesthetised for i.p. injections in my study, 
which may have an anti-inflammatory influence (Hofstetter, 2007). An alternative 
approach that would provide a positive control for future studies is to administer LPS 
in a single acute dose, where the peak of the inflammatory response is thought to 
be between 8 and 24 hours post administration (Buttini et al., 1996). We would be 
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able to compare these results to previous experiments demonstrating acute LPS 
induced responses (Kozlowski and Weimer, 2012; Zhu et al., 2014). 
Limitations 
A limitation of the Cell Profiler analysis is that quantification was conducted on 2D 
images rather than in 3D. This is a potential confound as the entire cell may not be 
contained in the ROI and overlapping cells may be less accurately quantified. The 
use of a DAPI channel reduces this problem to an extent, however full 3D analysis 
would be ideal. The dose of Haloperidol is relatively low, which was chosen to 
provide a striatal D2 occupancy similar to that achieved in the clinic (Kapur et al., 
2003). While this provides a better clinical interpretation, it is significantly lower than 
that used in the animal and in vitro literature to date (Hou et al., 2006). This makes 
interpretation of our findings more difficult. However the blood doses of haloperidol 
we see in our animals is comparable to the lower end of the clinical literature (Coryell 
et al., 1998). 
The drug delivery in this study was via subcutaneous drug pellets. These pellets use 
a matrix driven delivery (MDD, Innovative research of America, Florida USA) system 
(Singh et al., 2008), where the contents are released over a period of time when 
inserted subcutaneously. The use of continuous delivery is not ubiquitous in 
antipsychotic literature and is, in some cases, considered to be less effective and 
more subject to tolerance effects (Samaha et al., 2008). In this context we were 
looking for a paradigm which would approximate the medication dynamics in patient 
cohorts. Through to the end of the experiment blood levels of haloperidol were 
detectable, at a consistent low level. As with the general antipsychotic literature, the 
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literature using IRA pellets implements a range of doses of haloperidol (Adán et al., 
2013; Liskowsky and Potter, 1987), the one used here is low in comparison but 
seems effective. For many of the animals pellets were recovered post dissection. In 
some animals the pellet may have fully dissolved or merely was not distinguishable 
during dissection. The study presented here investigates the effects of haloperidol 
at a single time point, it would however be useful to have a longitudinal design of 
study to determine when the brain and potential glial changes first occur. Previous 
investigations of brain volume using haloperidol and MRI in rats demonstrated a 
return to baseline volume after drug withdrawal (Vernon et al., 2011). It would be 
interesting to see how microglial cells would respond in this paradigm of 
administration-withdrawal. 
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Conclusions 
Here we demonstrate how microglial cell densities or soma sizes are not altered 
with haloperidol treatment. Interestingly there were brain volume reductions 
associated with haloperidol treatment, which may explain some of the cortical loss 
seen in medicated patients. The results suggest clinical investigation of cortical 
microglial cells may not be influenced by antipsychotics but brain volumes may well 
be reduced. 
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Chapter 6 – Summary discussion conclusion 
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Summary of findings  
In this thesis, our main experimental questions were addressed. The three aims are 
presented below with a summary of the findings from the associated chapters; 
 
Aim 1: To determine whether neuroinflammation is present in subjects with 
subthreshold psychotic symptoms, using PET imaging with the 2nd generation TSPO 
ligand [11C]PBR28.  
 
Results: Relative to age and genotype matched healthy controls, [11C]PBR28 signal 
was significantly elevated in UHR subjects. Whole brain normalized VT was used to 
provide a DVR of [11C]PBR28 with 2TCM-1k analysis. Significant elevations of 
[11C]PBR28 signal were observed in total grey matter, frontal lobe and temporal lobe 
regions of interest. No cerebellar difference was observed, suggesting elevations 
are of a specific origin. Similarly, medicated patients with schizophrenia 
demonstrated elevations of [11C]PBR28 in the same regions of interest when 
compared with a second cohort of matched control subjects.  
 
Aim 2: To assess the relationship between [11C]PBR28 signal and symptom severity, 
cortical structure alterations and peripheral inflammatory measures in patients and 
UHR subjects. 
 
Results: There were elevations in peripheral TNF-α in UHR and patients with 
schizophrenia. Patients with schizophrenia demonstrated significant cortical volume 
reduction in whole grey matter. This correlation was not present in control of 
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schizophrenia groups. Peripheral measures didn’t correlate with volume or PET 
signal. 
 
Aim 3: To determine the effects of haloperidol treatment on microglial cells and 
cerebral volume in naïve and inflamed rat brain tissue. 
 
Results: Haloperidol reduced brain volume in naïve rats, of a magnitude similar to 
findings in the literature (~20%). We designed Cell Profiler software pipelines to 
provide accurate quantification of cell density, cell body area and cell body stain 
intensity. This provided an accurate and precise workflow for the assessment of 
haloperidol treated tissue. Haloperidol did not alter microglial cell density, soma size 
or stain intensity in the prefrontal cortex in naïve or LPS inflamed tissue. There was 
no reduction in total number of nuclei in haloperidol animals, suggesting volume 
loss is not through a reduction in total number of cells. Further investigation is 
required to determine the mechanism of reduction of brain volume. 
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Discussion 
The research questions within this thesis cover a number of research themes, from 
the basic function of specific cell types to cortical alterations in a complex psychiatric 
illness. The discussion of these topics will be addressed in the order presented in 
the body of work and then combined to produce a more integrative perspective.  
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Clinical study discussion 
In the clinical study we have demonstrate how microglial activity is elevated in 
subjects prior to the onset of first episode psychosis, as measured through PET 
imaging of TSPO. Here we discuss the implications of this finding and future 
investigations which could be conducted on the topic. 
Neuroinflammation in psychosis 
As we saw in the introductory chapter, there is considerable evidence that 
neuroinflammation is a component of schizophrenia, from post mortem (Bayer et 
al., 1999; Steiner et al., 2006) and in vivo PET imaging studies (Doorduin et al., 
2009; van Berckel et al., 2008). Peripheral inflammatory markers are also elevated 
in patients with schizophrenia and those with prodromal psychotic symptoms 
(Cannon et al., 2015). TSPO is used as the PET imaging target for microglial activity 
and has been used to demonstrate neuroinflammation in a range of disorders. To 
date, psychosis has not been investigated in pre-first episode subjects. The present 
thesis investigates the role of neuroinflammation in association with the TSPO 
binding ligand [11C]PBR28 in UHR subjects and patients with schizophrenia. 
The findings indicate that both patients with schizophrenia and UHR subjects have 
elevated whole brain grey matter, frontal lobe and temporal lobe binding compared 
to matched healthy controls. There are a number of caveats which will be discussed, 
however the greatest limitation for interpreting our finding is that UHR subjects will 
not all develop a psychotic disorder, hence cannot be viewed as a prodrome. In this 
investigation, the transition rate to psychosis to date is 7%, which is far lower than 
the rates reported in the literature (20-35%) (Wood et al., 2008; Yung et al., 2005). 
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The low transition rates we see may be a consequence of our subjects being 
recruited from an early intervention service, where various forms of medication and 
cognitive treatment are used to prevent first episode transition. In the interval from 
scanning a number of UHR subjects started on antipsychotics. In the UHR group, 
symptom severity was positively correlated with [11C]PBR28 signal, however this 
relationship was not present in patients with schizophrenia. There is a possibility 
that this is related to medication, as UHR subjects were antipsychotic naïve and 
patients were on a range of medication. The literature suggests an anti-inflammatory 
role of antipsychotics in vitro (Kato et al., 2007), the latter chapters of this thesis 
confirm this in vivo for haloperidol. The patients with schizophrenia and UHR 
subjects investigated ultimately are heterogeneous groups, where none were 
acutely psychotic, hence may not be truly reflective of psychosis. Beyond psychosis, 
there is evidence that microglia are involved with depression (Setiawan et al., 2015) 
and may prove to be a feature of general psychiatric illness.  
Future directions 
The evidence for the involvement of microglia in psychosis is compelling and 
demonstrates, for the first time, that microglial activity is associated with psychotic-
like symptoms presenting before an episode of frank psychosis. While this is an 
interesting finding, it is crucial to determine how this is related to outcome. We have 
had 1 subject transition to first episode psychosis, and interestingly, this subject had 
the highest [11C]PBR28 binding. A possible future investigation would be to perform 
longitudinal follow up to determine whether subjects transitioning continue to 
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develop elevations in microglial activity, as well as seeing whether those discharged 
from psychiatric services have levels which return to those of controls. 
[11C]PBR28 is still a relatively novel ligand for PET imaging, hence the precise 
details of tracer specificity and signal to noise ratio are unclear. A small study has 
been conducted to determine the ratio of specific to non-specific ratio of binding 
(Owen et al., 2014). However it is not known whether this level of specific and non-
specific binding is consistent across clinical cohorts. Hence it would be valuable to 
conduct a similar blocking study with [11C]PBR28 in our cohorts to determine these 
signal components. 
As TSPO is elevated prior to the onset of first psychotic episode, it is therefore a 
potential therapeutic target. TSPO is involved in steroidal transport, however acts 
as a marker of inflammation in the brain. Hence it is possible to investigate whether 
anti-inflammatories may be able to prevent transition or ameliorate symptoms in 
UHR subjects, or maybe be applied to patients with schizophrenia. The latter 
investigation has been performed in a small cohort, using minocycline, and proved 
successful in treating symptoms assessed on the PANSS (Miyaoka, 2008). 
Limitations 
PET methodology issues 
Second generation TSPO ligands have proven difficult to analyse. A larger affinity 
has produced profound difficulties when assessing signal to noise ratios and 
specificity of signal. Indeed many studies conducted using second generations 
ligands have not demonstrated differences with VT as the outcome measure 
(Hannestad et al., 2013; Kenk et al., 2015; Park et al., 2015a; Takano et al., 2010). 
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This has raised concern over the use of such ligands, however there has been 
progress in addressing the issue of noise by using normalization approaches, such 
as the DVR approach used in this thesis. Two recently published studies have 
demonstrated the use of the cerebellum (Lyoo et al., 2015) and, as we have here, 
the whole brain signal (Loggia et al., 2015). 
TSPO Genotyping 
The brain TSPO that [11C]PBR28 binds to is affected by an SNP in the general 
population, 10% being LABs, 40% being MABs and 50% being HABs (Owen et al., 
2011). The results of our investigation demonstrated a very close proportional 
representation here (7% LAB, 37%MAB & 56% HAB). We scanned mid and high 
binders and co-varied in analysis rather than stratifying groups. This decision was 
made to provide a more representative sample for the clinical population, the 
analysis of a stratified UHR group did not differ to those of the combined analysis 
and data from differing genotypes overlapped considerably. 
TSPO & microglial distribution 
A major limitation of TSPO imaging studies is the relationship between microglia at 
the cellular level and the signal from scanning. Preclinical investigation has 
demonstrated TSPO presence on a range of cell types. With expression detected 
on astrocytes, microglia and neural progenitor cells. TSPO is also expressed in 
relatively low concentrations in the brain, tissues with higher expression include 
adrenal glands and testes (steroid synthetic tissues) (Banati et al., 2014). 
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Comorbidity and cohort validity 
Patient cohorts are variable and patients with schizophrenia are particularly 
heterogenous. In the investigations here, we have controlled for or minimized 
variability where possible, however there are inevitably caveats and variables which 
cannot be controlled. Larger cohorts of participants could be stratified, however it is 
not a simple objective task. 
When using a clinical cohort for a study such as this, it is very often patients that 
are high functioning and at experiencing less severe stages of the disorder that are 
able to participate. This is partly a consequence of ease of investigation, but also 
an ethical consideration. The patients that are potentially the most interesting in 
terms of function and psychopathology are often not of consenting capacity. Hence 
such individuals are not able to take part in research. 
Schizophrenia as a disease is affected by a number of comorbid health risks, some 
of which arise as a consequence of medication, however many are closely related 
to features of disease. 
A small number of subjects in our patient cohort were taking medication for diabetes. 
Comorbidity of diabetes and schizophrenia is relatively common, indeed there is an 
association between antipsychotic medication and diabetic status in patients with 
schizophrenia (Llorente and Urrutia, 2006). As with diabetes, obesity is present in 
higher proportions in patients with schizophrenia, there is evidence that obesity and 
inflammation are associated (Lim and Marsland, 2013; Thaler et al., 2013; Vgontzas 
et al., 1997), however the literature is somewhat conflicting in the role of TSPO in 
this context (Lassance et al., 2015). Similar to obesity, there are age associated 
changes in inflammatory status, with a greater level of cortical inflammation in later 
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life, which has been studied with PET using [11C]-(R)-PK11195 (Schuitemaker et al., 
2012). 
A number of patients and UHR subjects reported use of recreational substances, 
where the control cohorts did not. Cocaine use and cannabis use were the two most 
frequently reported drugs. The former has been shown to have no relationship with 
[11C]PBR28 (Narendran et al., 2014). However cannabinoids are potentially 
inhibitory to reactive gliosis (Gomes et al., 2015), PET evidence is yet to be 
published on this topic. While use of cannabis may influence microglial activity, the 
effects would reduce levels and would serve to reduce the margin between control 
and experimental groups. 
PBR28 ligand and analysis methods 
The use of TSPO as a marker has raised a number of issues in assessing microglial 
activity. PK11195 was not optimum for in vivo investigation, hence the development 
of a second generation of TSPO tracers. Unfortunately, the second generation has 
not delivered in the ways expected, particularly PBR28. The affinity of PBR28 is 
higher than PK11195, however this results in considerable noise and non-specific 
binding. Further than this, the SNP affecting affinity binding makes PBR28 a tedious 
ligand to work with, as genotyping subjects prior to scanning can prove troublesome, 
particularly in patient cohorts, where attendance is unpredictable. We have 
discussed these methods in (Turkheimer et al., 2015). 
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Animal study discussion 
In these experiments we have investigated microglia following antipsychotic 
administration in inflammatory and naïve contexts. The role of microglia in the 
healthy and diseased brain has received a lot of attention recently. New discoveries 
regarding microglia in synapse organisation (Parkhurst et al., 2013) has revealed 
how crucial microglia are to brain function. The clinical investigations in this thesis 
demonstrate a change in microglial activity prior to the onset of psychosis, however 
the role of antipsychotic mediation was an uncontrollable variable in the patient 
cohort. We administered haloperidol at a low, clinically comparable (Kapur et al., 
2003), dose for two weeks. Our inflammatory setting was not intended to be a model 
of psychosis or schizophrenia, however was designed to produce a cellular 
morphology which has been described in post mortem schizophrenia tissue 
examination (Bayer et al., 1999; Steiner et al., 2008; Steiner et al., 2006). 
Unfortunately the LPS administration did not produce the desired effect reported in 
(Chen et al., 2012) The primary aim of the animal investigations was to determine 
the in vivo effects of a low dose of antipsychotic medication on microglia. We also 
demonstrated how haloperidol administration is associated with cortical volume 
reduction. 
Mechanistic considerations 
Haloperidol is associated with reduced brain volume, however the mechanism of 
this alteration is unclear. Nuclear counting did not reveal a difference between 
treatment groups, suggesting reductions are not a result of a lower overall number 
of brain cells. 
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Neuron glial interaction 
Microglia-neuron interactions are able to modulate neuronal signalling, particularly 
in the spinal cord where peripheral signals relay sensory inputs (Staniland et al., 
2010). Work in the field of pain signal transduction has revealed immune cell 
mediated modulation in the CNS (Sheridan and Murphy, 2013; Sheridan et al., 
2014). It is not only the interaction between neurons and microglia to consider, as 
there is potential for astrocytic and oligodendrocytic consequences as well. 
Future directions 
The major outstanding question of the animal investigations is how the changes in 
brain volume occur with haloperidol treatment. In translating the findings from the 
animal experiments to the clinical setting, it is also essential to determine how 
medication and brain volume directly relate in patients. Additionally it is unclear how 
cortical volume changes with age or disease phenotype. 
Limitations 
Beyond the direct translation of biological information, there are a number of 
considerations when interpreting clinical and animal findings together. The animals 
are 2-3 months old (250g), which corresponds to a young adult or late adolescent 
period (Sengupta, 2013). The patients receiving medication were on average 45 
years old. Age matching is a major consideration for clinical investigation, 
particularly when investigating volumetric changes and inflammation, as there are 
large age effects on both features. Animal equivalent years are difficult to translate, 
however it would be desirable to use animals of a greater age as it has recently 
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been demonstrated that the same age-microglial association is present in rats 
(Walker et al., 2015). 
As with our imaging experiments, the animal investigation was of a cross sectional 
design. The changes we see are from a single time point following chronic 
administration of medication. It would be useful to determine the time point where 
volume changes or microglial reductions first occur. For this we would need to 
implement the non-invasive methods used in the clinical studies. While this gains 
temporal resolution, our spatial resolution for brain volume/microglial cell 
assessment would be hindered. However we would be able to perform direct 
comparisons at the endpoint between animal PET of TSPO and tissue staining for 
microglia. 
The patients with schizophrenia in the clinical study were receiving a myriad of 
medication, many of which were second generation antipsychotics with diverse 
receptor antagonism profiles. In our investigation we administered haloperidol, 
which is more specific in its action at DRD2 than second generation counterparts 
(Miyamoto et al., 2012). It would be useful to conduct the investigation with multiple 
first and second generation antipsychotics, over a range of doses to apply more 
directly to the nature of clinical administration. 
  
Neuroinflammation and psychosis; antipsychotic medication. Peter Bloomfield 
 
195 
 
Translational discussion 
Implementing research in a translational manner is open to interpretation and 
criticism as comparing human findings directly to animals is not trivial. Modelling 
diseases, particularly of a psychiatric nature, are highly controversial, as the 
pathology and symptomatic expression are particularly unique to a human condition. 
It is unreasonable to say an animal model of schizophrenia is valid, as the complex 
symptoms that are features of psychosis are not assessable in animals. 
However, assessing pharmacology and consequences of medication, as in the 
investigations here, is less of a stretch. We will come to discuss the limitations of 
translation of our findings, however we can begin to interpret the two findings 
together. The clinical investigations demonstrate how microglial activity would 
appear to be associated with psychosis. In the UHR group this is associated with 
symptom severity, indeed the only subject to transition at this point had the highest 
[11C]PBR28 binding. This symptom relationship was not apparent in the patients with 
schizophrenia, where medication was a major caveat. To address this issue and 
determine the in vivo consequences of antipsychotic medication, we designed the 
animal experiments to determine the effects of the typical DRD2 antagonist 
haloperidol on microglia. We do not see haloperidol associated microglial changes, 
but do see a reduction in brain volume. If we take the clinical and animal findings 
together, antipsychotics would not appear to alter microglial activity in medicated 
patients. It would be useful to investigate different doses and receptor profile 
antipsychotics to investigate this to a greater extent.  
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Conclusion 
In conclusion my studies have shown that sub-threshold psychotic symptoms are 
related to the levels of neuroinflammation/microglial cell activity as measured by 
TSPO PET imaging. Haloperidol administration demonstrated a reduction in brain 
volume in animals, however microglial cells did not appear to be altered after 
treatment. Based on the present findings, prior to the onset of first episode 
psychosis cortical inflammation may provide a novel therapeutic target. 
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Appendix 1 
 
Microglial software development 
The physiology of microglia is complex, with context dependent activity observable 
in vitro and in vivo (Kettenmann et al., 2011). The myeloid origin of these cells makes 
many aspects of their physiological activity similar to that of macrophages and 
mononuclear cells found in the peripheral bloodstream (Ransohoff and Cardona, 
2010). Well characterised roles include phagocytosis of debris (Neumann et al., 
2009), migration to injured tissue (Nimmerjahn et al., 2005) and cytokine release 
(Davalos et al., 2005). However recent evidence has demonstrated how microglial 
cells are involved in mature synaptic dynamics (Tremblay et al., 2011). Indeed BDNF 
signalling has been demonstrated as functionally critical for microglial associated 
synaptic plasticity (Parkhurst et al., 2013). In these novel plastic roles, the 
morphology of cells is more closely related to a ‘ramified’ morphology (Figure 30), 
referred to in older literature as a resting state. 
  
Figure 30. Microglial processes and synapse interaction. 
C 
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Hypothesised roles for microglia, processes/synapses are physically associated 
through EM reconstruction (A/B) and hypothesised to play a role in synapse 
modulation (C). Adapted from (Kettenmann et al., 2013). 
 
Microglial cells are particularly difficult to quantify, as the morphology of the cells 
varies across the cortex (Lawson et al., 1990) as well as in response to exogenous 
stimuli (Kondo et al., 2011). Cell density is used routinely to assess the activity of 
microglia, however it is very hard to draw conclusions from this type of analysis as 
the functions of microglia can be incredibly diverse. Morphology may suggest a 
specific form of activity, however the morphological response does not seem to be 
linear or ubiquitous. This is further illustrated by ((Rey-Villamizar et al., 2014),Figure 
31) where, particularly evident in C, amoeboid cells and cells of high branch 
complexity are found abundantly in a close physical proximity. 
 
Figure 31. Microglial morphology variation in tissue  
Distribution of microglial morphologies using python based analysis from tissue with 
implanted neuroprosthetic devices. Adapted from (Rey-Villamizar et al., 2014) 
0 
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Histological assessment of microglia can be conducted using many antibodies and 
stains, however three main cellular markers are preferred for cortical quantification, 
Iba-1 (ionized calcium binding adaptor protein-1), CD68 (cluster of differentiation 
68) and cd11b (cluster of differentiation 11b). The cellular marker Iba-1 is one of the 
most commonly used markers for immunohistochemistry and is thought to represent 
microglial cells independent of state (Ito et al., 1998), meaning cells of all 
morphology type and activity state should be represented by the staining. CD68 and 
cd11b mark M1 type inflammatory responsive cells and microglia/macrophage cells 
respectively (Kobayashi et al., 2013; Perego et al., 2011). (Stence et al., 2001) used 
time lapse confocal imaging of microglia in hippocampal slices to demonstrate how 
morphological changes can occur rapidly (branch changes within minutes and cell 
motility occurring over hours).  
In vitro analysis can be quite easily implemented in an automated fashion using 
ImageJ/FIJI (NIH, USA) or similar tools, as background signal is lower than in tissue 
slices (Boizeau et al., 2013). When analysing tissue samples, reliable segmentation 
is necessary for accurate quantification. There are a number of features of microglia 
which are quantified in tissue sections, including density of cells in an ROI, the 
coverage of the ROI by the processes and the roundness of cell (Kozlowski and 
Weimer, 2012). While these methods can determine broad dissimilarity between two 
tissue types, individually they are not particularly descriptive or sensitive to subtle 
changes in tissue. For example, if assessing the response of microglia to a 
compound, it may be the case that the density of the cells is reduced, however the 
morphology and process coverage may become more complex, hence using the 
traditional methods of counting or coverage, the context would not be described so 
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accurately. A number of studies have attempted to develop software to analyse 
microglial cells using a range of assessment criteria. Table 17 outlines the methods 
used and the criteria analysed in each study. 
Automation is an attractive feature of most analysis techniques as it reduces bias, 
saves time and provides a standardised method for multiple end-users. While 
automation of analysis is an attractive prospect, there is the danger that 
serendipitous findings and familiarity with the imaged tissue may become limited 
when analysis is fully automated. 
We designed an automated software pipeline for the analysis of microglial cells. Cell 
density, cell body size, cell body stain intensity and cell process complexity will be 
the cellular features identified in the software, as highlighted by the literature review 
as useful markers of microglial cells.
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Study Software used/method of 
detection 
Automated? Parameters assessed Context specificity 
(Rey-Villamizar et al., 
2014)  
Python, 3D segmentation 
of stacks; cellular 
characterization 
Partial Ramified cells – high complexity; 
Moderately complex cells; 
Activated cells of low complexity; 
Amoeboid cells without arbours 
Neuroprosthetic surgery, 4 
phenotypes 
(Karperien et al., 2013) Image J, FracLac software Partial Fractal linearity (‘DB’) A range of cellular 
phenotypes 
(Morrison and Filosa, 
2013) 
Image J, Analyzeskeleton 
and scholl analysis 
Partial Branch length Branch divisions; 
Area of cell spread 
Ischemic stroke inflammation 
(Kozlowski and 
Weimer, 2012)  
Matlab, 3D segmentation 
of stacks; morphological 
quantification 
Full Cell density (with nuclear 
colocalization); Cell area; 
Roundness; Cell body size; Stain 
intensity 
4 acute doses of LPS 
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Table 17. Studies quantifying microglial cells 
Description of detection, automation status, parameters of assessment and demonstration of context specific sensitivity.
(Paolicelli et al., 2011) Image J 3D particle 
analysis plugin 
Partial Stain colocalization; Microglial 
cell density (with nuclear 
colocalization) 
Developmental pruning 
(Tremblay et al., 2010)  Single cell reconstruction, 
Image J tracing & 
Reconstruct software 
No Process area (µm2); 
Colocalization of Spines and 
microglial processes (%) 
 
Plasticity interactions 
(Forero et al., 2010) Image J, DeadEasy Partial Cell density (with nuclear 
colocalization) 
Drosophilla mitotic glia 
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Software development. 
After assessing the software reported in the literature (Error! Reference source 
ot found.) we determined the following to be representative analysis parameters; 
 Soma size 
 Cell density 
 Soma intensity 
 Average branch length 
 
We inspected images of microglia and, as proposed by (Kozlowski and Weimer, 
2012), determined that a more accurate way to represent cell density was by using 
a DAPI channel colocalisation detection process. This ensures that all the cells 
quantified in the ROIs are indeed whole cells rather than larger clusters of processes 
captured in the volume. 
Images were acquired for a batch of slides in a single session, this was to prevent 
error in laser drift and changes in gain between sesions. Images acquired in different 
sessions would be produced from batches of slides with control animal tissue 
included to ensure comparison can be accurately made (it is important to image 
control samples with experimental groups in imaging, particularly for the intensity 
based quantification). 
Following acquisition, image files were converted to.tif image format as a maximum 
projection of the 11 plane stack. As a standardised identifyer, a suffix of _ch0 was 
added to low gain red channel images _ch1 was added to high gain red channel 
images and _ch2 was added to the DAPI images. 
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Cell Profiler Software pipeline steps 
1. Load images – Individual images were loaded from a source folder, with the 
DAPI channel and CY3 channel distinguishable for each image in the set. 
_ch0 and _ch2 image sets are given a RED or DAPI identifyer respectively. 
2. Correct illumination determination – RED images are normalized to a 
standard illumination to account for variation in field of view brightness 
variation (image brightness drops off in the corners as the objective has a 
circular aperture). The illumination is scaled according to a standardised 
polynomial. 
3. Correct illumination application – The illumination scaling is then applied 
to the RED image. 
4. Identify primary objects – Microglial associated staining in the image is then 
identified from the illumination corrected image, the lower threshold for cell 
detection is 9 pixels in diameter and the upper bound for inclusion is 50 pixels 
in diameter. These values were based on cell sizes reported in the literature 
(Karperien et al., 2013; Kozlowski and Weimer, 2012) as well as preliminary 
testing with our image files. Objects outside this diameter were discarded, as 
were cells in contact with the border of the image (this was to prevent analysis 
of incomplete cells). In this module, Otsu Adaptive thresholding (Otsu, 1979) 
was performed to distinguish cellular staining from background, with 0.25-1.0 
bounds on threshold. Clumped objects were distingushed in the red channel 
and the outlines of the red cells were overlaid on the illumination corrected 
image (Figure 32). 
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Figure 32. Microglial process area detection 
Resulting detection image produced from pipeline step 4: Identify primary objects.  
 
5. Measure object size & shape – The size and shape of the identified red 
objects are measured in this module. 
6. Filter objects – The red objects identified are then further filtered so that a 
minimum measurement of size is retained for subsequent analysis, this step 
ensures that smaller clusters of cell processes are not later counted as cells 
when colocalisation with DAPI is implemented. 
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The next three steps are implemented in the same manner for the DAPI channel as 
the red, however thresholds for identifying nuclei are marginally different.  
7. Correct illumination calculate – Same as red 
8. Correct illumination apply – Same as red 
9. Identify primary objects – The lower threshold for diameter is 5 pixels and 
the lower bound for thresholding is 0.08, ensuring all nuclei were detected. 
Clustered nuclei were identified through shape recognition. Outlines are then 
overlaid  and a nuclear outline image is saved. 
10. Pause cell profiler – At this stage the pipeline either pauses or continues, 
this step was implemented for the testing of software so that the full analysis 
was prevented from running once object identification had occurred. 
11. Mask objects – In this module, the nuclei are masked to create an image to 
analyse colocalisation from. 
12. Mask objects – In this module, the red cells are masked from the centre point 
of staining to provide an area to measure the cell soma. 
13. Measure objects size shape – This module measures the now masked red 
cells prior to colocalisation with DAPI nuclei to gain a could of stain density. 
This is to compare the accuracy of nuclear colocalisation, as previous 
methods reported in the literature often do not confirm whole cell presence 
with a nuclear channel. 
14. Filter objects – This module is a further size filter to ensure masked objects 
retain threshold criteria. 
15. Overlay outlines – The filtered red cell outlines and masked nuclei are 
overlaid in this module to produce a visual output of colocalization. The whole 
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cell spread including processess are outlined in white, the filtered cells are 
outlined in green and the nuclei are outlined in blue (Figure 33). 
 
Figure 33. Co-localised nuclear detection 
Overlaid nuclei and microglial cell stain processes from step 15: Overlay outlines 
16. Identify primary objects – This module assess the area in the image 
occupied by cell processes, as this method has previously been used as a 
criteria for quantifying cortical microglial cells. 
17. Measure objects size shape – The red cell process size and shape is 
quantified in this module. 
18. Measure object intensity – In this module, the intensity of the masked red 
cell soma intensity is quantified. 
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19. Overlay outlines – In this module a final image of the red cell process 
coverage is produced, with a red outline of all cell process coverage. 
 
20. Measure image area occupied – In this module, the full area of coverage is 
measured. 
21. Identify sencondary objects – In this module, the procecess (here labelled 
the dendritic tree) associated with specific red cells are measured. This is to 
provide a quantification of whole cell spread rather than all process 
occupancy in the image. 
22. Measure object size shape – The dendritic tree size and shape is measured. 
23. Overlay outlines – Overlay images of the dendritic tree are produced and 
added to the cell soma images, where the tree has a red outline, the soma 
has a green outline and the nucleus a blue outline. 
24. Save images – Cell body overlays are saved.  
25. Save images – Cell process image overlays are saved. 
26. Save images – Dendritic tree overlays are saved. 
27. Overlay outlines – In this module nuclear DAPI overlaid images are 
generated. 
28. Save images – DAPI nuclear outlined overlays are saved in this module 
(Figure 34). 
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Figure 34. Nuclear count detection 
DAPI Nuclei counting module image from stage 28: Save images. 
29. Export to spreadsheet – The measurements are exported to a comma 
seprated (.csv) spreadsheet for analysis, with the output in Figure 35; 
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Figure 35. Data output spreadsheet 
An excel file from the Cell Profiler based analysis pipeline. Where column A; area 
occupied, is the total area of process occupancy. Column B; area Occupied_Total, 
is the total area of the image analysed. Column C; Count_Cells_DendriticTree, is 
the number of cells with a dendritic tree record (the full data for dendtritic tree is 
produced in a separate spreadsheet). Column D; Count_Filtered, is the number of 
cells identified before the DAPI colocalization is applied. Column E; Count_Masked 
is the number of masked red cells with a DAPI nucleus colocalised. Column F; Count 
Nuclei; is the total number of nuclei in the DAPI channel. Column G/H are file and 
directory identifiers. 
Output/data 
The data is easily interpreted from a spreadsheet design and can be imported to 
SPSS, matlab or r studio for statistical testing. 
 
